
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Interleukin-12 encoded by the oncolytic virus VSV-GP enhances therapeutic antitumor efficacy by inducing CD8+ T-cell responses with a long-lived effector cell phenotype - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="1525484C8AF35A6305484C0036BA9E1A.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="jimmthercanc">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12366581/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Journal for Immunotherapy of Cancer">
<meta name="citation_title" content="Interleukin-12 encoded by the oncolytic virus VSV-GP enhances therapeutic antitumor efficacy by inducing CD8+ T-cell responses with a long-lived effector cell phenotype">
<meta name="citation_author" content="Jasmin Hatami">
<meta name="citation_author_institution" content="Institute of Virology, Medical University of Innsbruck, Innsbruck, Tirol, Austria">
<meta name="citation_author" content="Krishna Das">
<meta name="citation_author_institution" content="ViraTherapeutics GmbH, Rum, Tyrol, Austria">
<meta name="citation_author" content="Leonie Wolf">
<meta name="citation_author_institution" content="Institute of Virology, Medical University of Innsbruck, Innsbruck, Tirol, Austria">
<meta name="citation_author" content="Andreas Aufschnaiter">
<meta name="citation_author_institution" content="Christian Doppler Laboratory for Viral Immunotherapy, Institute of Virology, Medical University of Innsbruck, Innsbruck, Tirol, Austria">
<meta name="citation_author_institution" content="Department of Internal Medicine V, Tyrolean Cancer Research Center, Medical University of Innsbruck, Innsbruck, Tyrol, Austria">
<meta name="citation_author" content="Janine Kimpel">
<meta name="citation_author_institution" content="Institute of Virology, Medical University of Innsbruck, Innsbruck, Tirol, Austria">
<meta name="citation_author" content="Tobias Nolden">
<meta name="citation_author_institution" content="ViraTherapeutics GmbH, Rum, Tyrol, Austria">
<meta name="citation_author" content="Liesa-Marie Schreiber">
<meta name="citation_author_institution" content="Christian Doppler Laboratory for Viral Immunotherapy, Institute of Virology, Medical University of Innsbruck, Innsbruck, Tirol, Austria">
<meta name="citation_author" content="Brigitte Müllauer">
<meta name="citation_author_institution" content="Institute of Virology, Medical University of Innsbruck, Innsbruck, Tirol, Austria">
<meta name="citation_author" content="Elke Podgorschek">
<meta name="citation_author_institution" content="ViraTherapeutics GmbH, Rum, Tyrol, Austria">
<meta name="citation_author" content="Theresa Schwaiger">
<meta name="citation_author_institution" content="ViraTherapeutics GmbH, Rum, Tyrol, Austria">
<meta name="citation_author" content="Bart Spiesschaert">
<meta name="citation_author_institution" content="ViraTherapeutics GmbH, Rum, Tyrol, Austria">
<meta name="citation_author" content="Guido Wollmann">
<meta name="citation_author_institution" content="Christian Doppler Laboratory for Viral Immunotherapy, Institute of Virology, Medical University of Innsbruck, Innsbruck, Tirol, Austria">
<meta name="citation_author_institution" content="Department of Internal Medicine V, Tyrolean Cancer Research Center, Medical University of Innsbruck, Innsbruck, Tyrol, Austria">
<meta name="citation_author" content="Knut Elbers">
<meta name="citation_author_institution" content="ViraTherapeutics GmbH, Rum, Tyrol, Austria">
<meta name="citation_author" content="Dorothee von Laer">
<meta name="citation_author_institution" content="Institute of Virology, Medical University of Innsbruck, Innsbruck, Tirol, Austria">
<meta name="citation_author" content="Zoltán Bánki">
<meta name="citation_author_institution" content="Institute of Virology, Medical University of Innsbruck, Innsbruck, Tirol, Austria">
<meta name="citation_publication_date" content="2025 Aug 20">
<meta name="citation_volume" content="13">
<meta name="citation_issue" content="8">
<meta name="citation_firstpage" content="e010675">
<meta name="citation_doi" content="10.1136/jitc-2024-010675">
<meta name="citation_pmid" content="40835316">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12366581/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12366581/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12366581/pdf/jitc-13-8.pdf">
<meta name="description" content="Vesicular stomatitis virus (VSV) pseudotyped with the glycoprotein (GP) of the lymphocytic choriomeningitis virus (VSV-GP) represents a potent oncolytic virus (OV). Oncolytic virotherapy is an emerging anticancer approach that uses viruses to ...">
<meta name="og:title" content="Interleukin-12 encoded by the oncolytic virus VSV-GP enhances therapeutic antitumor efficacy by inducing CD8+ T-cell responses with a long-lived effector cell phenotype">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Vesicular stomatitis virus (VSV) pseudotyped with the glycoprotein (GP) of the lymphocytic choriomeningitis virus (VSV-GP) represents a potent oncolytic virus (OV). Oncolytic virotherapy is an emerging anticancer approach that uses viruses to ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12366581/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12366581">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1136/jitc-2024-010675"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/jitc-13-8.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12366581%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12366581/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12366581/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12366581/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-jimmthercanc.png" alt="Journal for Immunotherapy of Cancer logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Journal for Immunotherapy of Cancer" title="Link to Journal for Immunotherapy of Cancer" shape="default" href="https://jitc.bmj.com/" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">J Immunother Cancer</button></div>. 2025 Aug 20;13(8):e010675. doi: <a href="https://doi.org/10.1136/jitc-2024-010675" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1136/jitc-2024-010675</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22J%20Immunother%20Cancer%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22J%20Immunother%20Cancer%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22J%20Immunother%20Cancer%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22J%20Immunother%20Cancer%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Interleukin-12 encoded by the oncolytic virus VSV-GP enhances therapeutic antitumor efficacy by inducing CD8+ T-cell responses with a long-lived effector cell phenotype</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Hatami%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Jasmin Hatami</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Jasmin Hatami</span></h3>
<div class="p">
<sup>1</sup>Institute of Virology, Medical University of Innsbruck, Innsbruck, Tirol, Austria</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Hatami%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">Jasmin Hatami</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Das%20K%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Krishna Das</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Krishna Das</span></h3>
<div class="p">
<sup>2</sup>ViraTherapeutics GmbH, Rum, Tyrol, Austria</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Das%20K%22%5BAuthor%5D" class="usa-link"><span class="name western">Krishna Das</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wolf%20L%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Leonie Wolf</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Leonie Wolf</span></h3>
<div class="p">
<sup>1</sup>Institute of Virology, Medical University of Innsbruck, Innsbruck, Tirol, Austria</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wolf%20L%22%5BAuthor%5D" class="usa-link"><span class="name western">Leonie Wolf</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Aufschnaiter%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Andreas Aufschnaiter</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Andreas Aufschnaiter</span></h3>
<div class="p">
<sup>3</sup>Christian Doppler Laboratory for Viral Immunotherapy, Institute of Virology, Medical University of Innsbruck, Innsbruck, Tirol, Austria</div>
<div class="p">
<sup>4</sup>Department of Internal Medicine V, Tyrolean Cancer Research Center, Medical University of Innsbruck, Innsbruck, Tyrol, Austria</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Aufschnaiter%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Andreas Aufschnaiter</span></a>
</div>
</div>
<sup>3,</sup><sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kimpel%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Janine Kimpel</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Janine Kimpel</span></h3>
<div class="p">
<sup>1</sup>Institute of Virology, Medical University of Innsbruck, Innsbruck, Tirol, Austria</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kimpel%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">Janine Kimpel</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Nolden%20T%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Tobias Nolden</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Tobias Nolden</span></h3>
<div class="p">
<sup>2</sup>ViraTherapeutics GmbH, Rum, Tyrol, Austria</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Nolden%20T%22%5BAuthor%5D" class="usa-link"><span class="name western">Tobias Nolden</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Schreiber%20LM%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Liesa-Marie Schreiber</span></a><div hidden="hidden" id="id7">
<h3><span class="name western">Liesa-Marie Schreiber</span></h3>
<div class="p">
<sup>3</sup>Christian Doppler Laboratory for Viral Immunotherapy, Institute of Virology, Medical University of Innsbruck, Innsbruck, Tirol, Austria</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Schreiber%20LM%22%5BAuthor%5D" class="usa-link"><span class="name western">Liesa-Marie Schreiber</span></a>
</div>
</div>
<sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22M%C3%BCllauer%20B%22%5BAuthor%5D" class="usa-link" aria-describedby="id8"><span class="name western">Brigitte Müllauer</span></a><div hidden="hidden" id="id8">
<h3><span class="name western">Brigitte Müllauer</span></h3>
<div class="p">
<sup>1</sup>Institute of Virology, Medical University of Innsbruck, Innsbruck, Tirol, Austria</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22M%C3%BCllauer%20B%22%5BAuthor%5D" class="usa-link"><span class="name western">Brigitte Müllauer</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Podgorschek%20E%22%5BAuthor%5D" class="usa-link" aria-describedby="id9"><span class="name western">Elke Podgorschek</span></a><div hidden="hidden" id="id9">
<h3><span class="name western">Elke Podgorschek</span></h3>
<div class="p">
<sup>2</sup>ViraTherapeutics GmbH, Rum, Tyrol, Austria</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Podgorschek%20E%22%5BAuthor%5D" class="usa-link"><span class="name western">Elke Podgorschek</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Schwaiger%20T%22%5BAuthor%5D" class="usa-link" aria-describedby="id10"><span class="name western">Theresa Schwaiger</span></a><div hidden="hidden" id="id10">
<h3><span class="name western">Theresa Schwaiger</span></h3>
<div class="p">
<sup>2</sup>ViraTherapeutics GmbH, Rum, Tyrol, Austria</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Schwaiger%20T%22%5BAuthor%5D" class="usa-link"><span class="name western">Theresa Schwaiger</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Spiesschaert%20B%22%5BAuthor%5D" class="usa-link" aria-describedby="id11"><span class="name western">Bart Spiesschaert</span></a><div hidden="hidden" id="id11">
<h3><span class="name western">Bart Spiesschaert</span></h3>
<div class="p">
<sup>2</sup>ViraTherapeutics GmbH, Rum, Tyrol, Austria</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Spiesschaert%20B%22%5BAuthor%5D" class="usa-link"><span class="name western">Bart Spiesschaert</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wollmann%20G%22%5BAuthor%5D" class="usa-link" aria-describedby="id12"><span class="name western">Guido Wollmann</span></a><div hidden="hidden" id="id12">
<h3><span class="name western">Guido Wollmann</span></h3>
<div class="p">
<sup>3</sup>Christian Doppler Laboratory for Viral Immunotherapy, Institute of Virology, Medical University of Innsbruck, Innsbruck, Tirol, Austria</div>
<div class="p">
<sup>4</sup>Department of Internal Medicine V, Tyrolean Cancer Research Center, Medical University of Innsbruck, Innsbruck, Tyrol, Austria</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wollmann%20G%22%5BAuthor%5D" class="usa-link"><span class="name western">Guido Wollmann</span></a>
</div>
</div>
<sup>3,</sup><sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Elbers%20K%22%5BAuthor%5D" class="usa-link" aria-describedby="id13"><span class="name western">Knut Elbers</span></a><div hidden="hidden" id="id13">
<h3><span class="name western">Knut Elbers</span></h3>
<div class="p">
<sup>2</sup>ViraTherapeutics GmbH, Rum, Tyrol, Austria</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Elbers%20K%22%5BAuthor%5D" class="usa-link"><span class="name western">Knut Elbers</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22von%20Laer%20D%22%5BAuthor%5D" class="usa-link" aria-describedby="id14"><span class="name western">Dorothee von Laer</span></a><div hidden="hidden" id="id14">
<h3><span class="name western">Dorothee von Laer</span></h3>
<div class="p">
<sup>1</sup>Institute of Virology, Medical University of Innsbruck, Innsbruck, Tirol, Austria</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22von%20Laer%20D%22%5BAuthor%5D" class="usa-link"><span class="name western">Dorothee von Laer</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22B%C3%A1nki%20Z%22%5BAuthor%5D" class="usa-link" aria-describedby="id15"><span class="name western">Zoltán Bánki</span></a><div hidden="hidden" id="id15">
<h3><span class="name western">Zoltán Bánki</span></h3>
<div class="p">
<sup>1</sup>Institute of Virology, Medical University of Innsbruck, Innsbruck, Tirol, Austria</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22B%C3%A1nki%20Z%22%5BAuthor%5D" class="usa-link"><span class="name western">Zoltán Bánki</span></a>
</div>
</div>
<sup>1,</sup><sup>✉</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="aff1">
<sup>1</sup>Institute of Virology, Medical University of Innsbruck, Innsbruck, Tirol, Austria</div>
<div id="aff2">
<sup>2</sup>ViraTherapeutics GmbH, Rum, Tyrol, Austria</div>
<div id="aff3">
<sup>3</sup>Christian Doppler Laboratory for Viral Immunotherapy, Institute of Virology, Medical University of Innsbruck, Innsbruck, Tirol, Austria</div>
<div id="aff4">
<sup>4</sup>Department of Internal Medicine V, Tyrolean Cancer Research Center, Medical University of Innsbruck, Innsbruck, Tyrol, Austria</div>
<div class="author-notes p">
<div class="fn" id="fn1_pmc"><p>Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.</p></div>
<div class="fn" id="fn1"><p><strong>Supplement:</strong> Additional supplemental material is published online only. To view, please visit the journal online (<a href="https://doi.org/10.1136/jitc-2024-010675" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1136/jitc-2024-010675</a>).</p></div>
<div class="fn" id="fn4"><p>DvL is an inventor on a patent related to VSV-GP. GW serves as a scientific advisor for Boehringer Ingelheim GmbH. KD, TN, EP, TS, BS and KE are employees of ViraTherapeutics GmbH and Boehringer Ingelheim International GmbH. The other authors declare no competing interest.</p></div>
<div class="fn" id="cor1">
<sup>✉</sup><p class="display-inline">Dr Zoltán Bánki; <span>zoltan.banki@i-med.ac.at</span></p>
</div>
</div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2024 Sep 27; Accepted 2025 Jul 30; Collection date 2025.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>Copyright © Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.</div>
<p>This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See <a href="https://creativecommons.org/licenses/by-nc/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/licenses/by-nc/4.0/</a>.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12366581  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40835316/" class="usa-link">40835316</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>Abstract</h2>
<section id="sec1"><h3 class="pmc_sec_title">Background</h3>
<p>Vesicular stomatitis virus (VSV) pseudotyped with the glycoprotein (GP) of the lymphocytic choriomeningitis virus (VSV-GP) represents a potent oncolytic virus (OV). Oncolytic virotherapy is an emerging anticancer approach that uses viruses to eliminate cancer cells by direct cell lysis and induction of an antitumor immune response. Immunomodulatory cargos expressed by OVs hold the potential to further enhance this antitumor immune response.</p></section><section id="sec2"><h3 class="pmc_sec_title">Methods</h3>
<p>To evaluate interleukin-12 (IL-12) as an immunomodulatory cargo encoded by VSV-GP, we used a subcutaneous tumor model by mixing type I interferon (IFN) competent murine lung epithelial cells (TC-1), which are largely resistant to VSV-GP in vivo, with VSV-GP permissive IFN-α receptor knockout TC-1 cells (TC-1<em>ifnar1<sup>−/</sup></em><sup>−</sup>).</p></section><section id="sec3"><h3 class="pmc_sec_title">Results</h3>
<p>This mixed model supports prolonged viral replication and subsequent IL-12 production. Oncolytic virotherapy with VSV-GP and VSV-GP-IL12 of parental TC-1 tumors did not lead to tumor control, whereas virus treatment in the TC-1/TC-1<em>ifnar1<sup>−/−</sup></em> mixed tumors showed prolonged survival. Furthermore, VSV-GP-IL12 was even more effective than VSV-GP treatment. Analysis of CD8+ T cell responses revealed phenotypic differences of activated CD8+ T cells between VSV-GP and VSV-GP-IL-12 treatment, whereby VSV-GP-IL12-induced CD8+T cells displayed a phenotype described for long-lived effector cells (LLEC). Depletion experiments indicated that CD8+ T cells, and not NK cells, were responsible for the improved efficacy observed with VSV-GP-IL12 treatment.</p></section><section id="sec4"><h3 class="pmc_sec_title">Conclusions</h3>
<p>Taken together, we have demonstrated that oncolytic virotherapy using VSV-GP encoding IL-12 induces CD8+ T cell responses characterized by an LLEC phenotype, a cell population that is likely a crucial component of antitumor immunity.</p></section><section id="kwd-group1" class="kwd-group"><p><strong>Keywords:</strong> Oncolytic virus, Immune modulatory, T-Lymphocytes, Combination therapy, Adaptive</p></section></section><hr class="headless">
<section class="bt xbox font-sm" id="BX1"><section id="sec5"><h2 class="pmc_sec_title">WHAT IS ALREADY KNOWN ON THIS TOPIC</h2>
<ul class="list" style="list-style-type:disc"><li><p>Oncolytic virotherapy is an emerging anticancer strategy that uses viruses like vesicular stomatitis virus (VSV)-glycoprotein (GP) to kill cancer cells and stimulate antitumor immune responses. Arming such oncolytic viruses with immunomodulatory agents like interleukin (IL)-12 may enhance their therapeutic efficacy, but the immune mechanism involved is not fully understood.</p></li></ul></section><section id="sec6"><h2 class="pmc_sec_title">WHAT THIS STUDY ADDS</h2>
<ul class="list" style="list-style-type:disc"><li><p>Our study reveals that VSV-GP encoding IL-12 (VSV-GP-IL12) improves the efficacy of oncolytic virotherapy in a mixed tumor model where IL-12 production is sustained. It demonstrates that VSV-GP-IL12 treatment promotes the induction of CD8+ T cells characterized by a long-lived effector cell (LLEC) phenotype.</p></li></ul></section><section id="sec7"><h2 class="pmc_sec_title">HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY</h2>
<ul class="list" style="list-style-type:disc"><li><p>Our findings have significant implications for understanding how IL-12 improves cancer immunotherapies. The insight into how IL-12 drives the generation of CD8+ T cell with an LLEC phenotype holds promise for the development of strategies that harness robust antitumor immune responses.</p></li></ul></section></section><section id="s1"><h2 class="pmc_sec_title">Background</h2>
<p> The field of oncolytic virotherapy has gained substantial momentum in recent years with the clinical approval of the first oncolytic virus (OV), based on a herpes simplex virus (HSV-1) (Talimogene laherparepvec; Imlygic) and its augmented therapeutic potential when combined with other immunotherapies.<a href="#R1" class="usa-link" aria-describedby="R1"><sup>1</sup></a> OVs use a combination of direct and indirect mechanisms to combat malignancies. In addition to tumor-selective viral replication and tumor elimination, OVs activate both innate and adaptive immunity.</p>
<p>Vesicular stomatitis virus pseudotyped with the glycoprotein (GP) of the lymphocytic choriomeningitis virus (vesicular stomatitis virus (VSV)-GP) is a promising OV currently undergoing phase 1 clinical testing.<a href="#R2" class="usa-link" aria-describedby="R2"><sup>2</sup></a> This genetic modification completely abrogates VSV’s neurotoxicity while preserving its oncolytic potential, as demonstrated across diverse preclinical tumor models.<a href="#R3" class="usa-link" aria-describedby="R3">3</a>,<a href="#R6" class="usa-link" aria-describedby="R6">6</a> The absence of pre-existing immunity in the general population and the weak neutralizing antibody induction against GP makes systemic delivery feasible.<a href="#R3" class="usa-link" aria-describedby="R3">3</a>,<a href="#R5" class="usa-link" aria-describedby="R5">5</a> Tumor selectivity of VSV predominately relies on the impaired type-I interferon (IFN) pathway commonly found in malignant cells.<a href="#R7" class="usa-link" aria-describedby="R7"><sup>7 8</sup></a> The success of OV therapies is intricately tied to the dynamic interplay between the virus itself, the tumor microenvironment (TME) and the immune system.<a href="#R9" class="usa-link" aria-describedby="R9"><sup>9 10</sup></a> Besides direct tumor cell killing, the viral oncolytic activity releases tumor-associated antigens from the dying cells. These tumor-associated antigens are thought to be captured by antigen-presenting cells, potentially triggering adaptive antitumor immune responses that could eliminate remaining malignant tumor cells.<a href="#R11" class="usa-link" aria-describedby="R11"><sup>11</sup></a></p>
<p>OVs can be armed with immunomodulatory cargos to boost the antitumor immune response. A highly effective immune stimulatory molecule is interleukin-12 (IL-12). IL-12 is a potent cytokine playing a pivotal role in the defense against infections and malignancies. Produced primarily by antigen-presenting cells in response to pathogens, IL-12 leads to the activation and proliferation of natural killer (NK) cells and T lymphocytes.<a href="#R12" class="usa-link" aria-describedby="R12">12</a>,<a href="#R14" class="usa-link" aria-describedby="R14">14</a> This activation leads to the differentiation of naïve T cells into cytotoxic T cells and Th1 subsets, laying the foundation for a robust cell-mediated immune response and the production of IFN-γ. IFN-γ not only supports the immune responses, but also augments the cytotoxic abilities, contributing significantly to the eradication of infected and/or neoplastic cells.<a href="#R15" class="usa-link" aria-describedby="R15">15</a>,<a href="#R17" class="usa-link" aria-describedby="R17">17</a></p>
<p>Despite its potential in cancer immunotherapy, the systemic clinical application of IL-12 is limited by immunotoxicity.<a href="#R18" class="usa-link" aria-describedby="R18"><sup>18 19</sup></a> Therefore, intratumoral delivery of recombinant IL-12 has been examined, but rapid clearance led to insufficient dwell time at the injection site, resulting in suboptimal antitumor response.<a href="#R20" class="usa-link" aria-describedby="R20"><sup>20</sup></a> Thus, strategies to optimize safe IL-12 delivery by incorporating the cytokine as transgene into viral vectors or using controlled release hold significant promise to reduce systemic toxicities while enhancing local antitumor immune response and therapeutic outcome.</p>
<p>Therefore, VSV-GP encoding IL-12 was tested in a subcutaneous TC-1 tumor model. To overcome the limitation of in vivo permissiveness of VSV-GP in TC-1 cells,<a href="#R3" class="usa-link" aria-describedby="R3"><sup>3 4</sup></a> we used a mixed tumor setting whereby TC-1 cells, which are IFN competent and relatively resistant to VSV-GP in the mouse, were combined with VSV-GP-permissive IFN-α receptor knockout TC-1 cells (TC-1<em>ifnar1<sup>−/−</sup></em>). Using this mixed tumor model, we found improved therapeutic efficacy of VSV-GP-IL12 compared with VSV-GP treatment. The enhanced tumor control observed with VSV-GP-IL12 was associated with a phenotype of CD8+ T cells similar to that previously described for long-lived effector cells (LLECs)<a href="#R21" class="usa-link" aria-describedby="R21"><sup>21 22</sup></a> or terminally differentiated effector memory cells (terminal-TEM)<a href="#R23" class="usa-link" aria-describedby="R23"><sup>23</sup></a> induced during lymphocytic choriomeningitis virus (LCMV) infection.</p></section><section id="s2"><h2 class="pmc_sec_title">Methods</h2>
<section id="s2-1"><h3 class="pmc_sec_title">Cell lines</h3>
<p>TC-1 cells (kindly provided by Dr T C Wu, Johns Hopkins University, Baltimore, Maryland, USA) were cultured in complete Roswell Park Memorial Institute (RPMI) 1640 (ThermoFisher Scientific, Waltham, USA) supplemented with 0.4 mg/mL G418, 10% FCS, 2 mM L-glutamine, 1% sodium pyruvate, and 1% MEM NEAA. TC-1<em>ifnar1<sup>−/−</sup></em> cells were generated by CRISPR/Cas9 vectors using plasmid transfection with pSpCas9(BB)−2A-GFP (PX458) (Addgene plasmid #48138; Watertown, USA) targeting three IFNAR1 regions from exon 2 and 3 as described before.<a href="#R24" class="usa-link" aria-describedby="R24"><sup>24</sup></a> Single-cell clones were collected after sorting (FACS Aria; BD Biosciences, Schwechat, Austria) for IFNAR negative clones using anti-IFNAR1 mouse (1:250, MAR1–5A3, BioLegend, San Diego, California, USA) and APC-conjugated goat anti-mouse-IgG1 (1:100, Jackson ImmunoResearch, Suffolk, UK) antibodies. Expanded clones were further characterized functionally for limited IFN sensitivity by incubation with universal IFN-α A/D (PBL, Piscataway, New Jersey, USA) overnight followed by MTT viability assay and fluorescence microscopy after VSV-GP-Green-Fluorescent Protein (GFP) infection as described previously.<a href="#R3" class="usa-link" aria-describedby="R3"><sup>3</sup></a> Four clones were selected and tumorigenicity was confirmed compared with the parental TC-1 cells.</p></section><section id="s2-2"><h3 class="pmc_sec_title">Recombinant viruses</h3>
<p>Replication-competent recombinant viruses VSV-GP, VSV-GP encoding HPV E7 as vaccine (Vacc), VSV-GP-GFP, and VSV-GP-Luciferase (VSV-GP-Luc) as well as VSV-ΔG-GFP have been described elsewhere.<a href="#R5" class="usa-link" aria-describedby="R5"><sup>5 8 25</sup></a> For the generation of VSV-GP-IL12, the coding sequence of a (G4S)3 linked mouse p40-p35 IL-12 heterodimer was de novo synthesized at Geneart/Thermo Fisher (Regensburg, Germany) as codon-optimized linear DNA fragment already flanked by VSV-specific sequences. The IL-12 DNA string was introduced into an NheI:XhoI linearized VSV-GP complementary DNA vector backbone using the NEBuilder HiFi DNA Assembly Cloning Kit (New England Biolabs, Ipswich, Massachusetts, USA) according to manufacturers’ recommendations. Vector identity was confirmed by Sanger sequencing before virus recovery.</p>
<p>Recombinant virus variants were recovered by a helper virus-free calcium phosphate co-transfection in 293T cells with expression plasmids of T7 polymerase (10 µg), VSV-N (2.8 µg), VSV-P (1.8 µg), VSV-L polymerase (0.6 µg) and with the respective transgenic construct containing the VSV-GP vector (10 µg) as described previously.<a href="#R26" class="usa-link" aria-describedby="R26"><sup>26</sup></a> After detection of a VSV-induced cytopathic effect (CPE) and expansion on HEK293-F cells, virus progeny was plaque-purified twice and amplified on HEK293-F cells. For quantification, the TCID50 assay was performed as described previously.<a href="#R8" class="usa-link" aria-describedby="R8"><sup>8</sup></a> In short, 100 µL of serial dilutions of virus were added in replicates to 10<sup>3</sup> BHK-21 cells seeded in a 96-well plate. 3 days after infection, cell culture plates were checked for VSV-induced CPE and titers were calculated according to the method of Spearman and Kärber.<a href="#R27" class="usa-link" aria-describedby="R27"><sup>27</sup></a></p>
<p>For virus amplification, HEK293-F cells were cultured in BalanCD medium (Irvine Scientific) supplemented with 4 mM GlutaMax (Gibco) in Erlenmeyer shake flasks (Corning). Cells were seeded at 4×10<sup>5</sup> cells/mL, incubated at 37°C with 5% CO<sub>2</sub> on a shaker set to 120 rpm for 48 hours prior to infection. The cell culture was infected with the stock virus at multiplicity of infection (MOI) 0.0005 and then returned to the shaking incubator for 32 hours until harvest. To harvest the virus particles in the supernatant, 0.2 M NaCl was supplemented into the culture and returned to the shaking incubator for 10 min. Then the suspension culture was clarified by centrifugation (2,000 g for 5 min), and then filtered through a 0.2 µm PES membrane. The clarified supernatant was then underlaid with a 20% sucrose solution in 50 mM Tris/HCl with 50 mM NaCl and centrifuged in cooled conditions (4–8°C) at 4,700–5,000 rpm, without brakes for 15–16 hours. The supernatant was discarded, and the virus-containing pellets were resuspended in a formulation buffer (50 mM Tris, 50 mM NaCl, 150 mM arginine, pH 7.5).</p></section><section id="s2-3"><h3 class="pmc_sec_title">Mice and ethic statements</h3>
<p>6–8 weeks old female C57BL/6JRj (Janvier, France) were housed in individually ventilated cages in a conventional, BSL2 infectious agent facility at the animal facilities of the Medical University of Innsbruck. Animal experiments were performed in accordance with the approval of the ethics committees of the Medical University of Innsbruck and the Austrian Federal Ministry of Science and Research under the licenses BMBWF-66.011/0156-V/3b/2019 and 2022–0.292.703. The experiment shown in the <a href="#SP1" class="usa-link">online supplemental figure S1A</a> was approved by the Institutional Animal Care and Use Committee of Oncodesign (Oncomet) and by the French authorities (CNREEA agreement N°91).</p>
<section id="s2-3-1"><h4 class="pmc_sec_title">In vivo studies</h4>
<p>For tumor implantation, mice were injected subcutaneously in the right flank with 1×10<sup>5</sup> TC-1 cells alone or a mix of TC-1 and TC-1<em>ifnar1<sup>−/−</sup></em> cells at ratios of 80:20 or 20:80 percent. In the bilateral tumor model, mice were subcutaneously implanted in the left flank with 1×10<sup>5</sup> TC-1 cells alone and in the right flank with a mix of TC-1 and TC-1<em>ifnar1<sup>−/−</sup></em> cells at a ratio of 80:20 percent. Mice were treated intravenously on day 10 or 11 post transplantation at a tumor size of around 0.05 cm<sup>3</sup> either with 100 µL phosphate-buffered saline (PBS), 1×10<sup>7</sup> TCID<sub>50</sub> VSV-GP or VSV-GP-IL12. In the bilateral tumor model, mice were treated at 10 days intravenously either with PBS (control), or in combination of E7-encoding VSV-GP-based cancer vaccine (Vacc) with VSV-GP (Vacc/GP) or VSV-GP-IL12 (Vacc/GP-IL12) in a 1:1 ratio with a TCID<sub>50</sub> of 1×10<sup>7</sup> from each component. Tumor growth was monitored by measuring the tumor diameter three times per week using a caliper and the tumor volume was calculated by the following formula: 0.4×length×width<sup>2</sup>. Animals were euthanized by CO<sub>2</sub> asphyxiation followed by cervical dislocation. Detailed additional information is provided in compliance with ARRIVE guidelines in supplemental methods (<a href="#SP1" class="usa-link">online supplemental methods S1</a>).</p></section></section><section id="s2-4"><h3 class="pmc_sec_title">Depletion of natural killer and CD8+ T cells in vivo</h3>
<p>For natural killer (NK) or CD8+ T cell depletion, mice were intraperitoneally injected either with anti-NK1.1 (clone PK136, 250 µg/treatment; Bio X Cell, West Lebanon, New Hampshire, USA) or anti-CD8 (clone YTS 169.4, 100 µg/treatment, Bio X Cell) or the combination of both antibodies in 100 µL PBS at day 8, 10, 14, 17 and 21 post tumor implantation. Isotype controls IgG2a (clone C1.18.4, 100 µg/treatment Bio X Cell) and IgG2b (clone LTF-2, 100 µg/treatment Bio X Cell) were also used. Depletion was confirmed via flow cytometry by gating either on the CD3<sup>pos</sup>CD8<sup>pos</sup> T cell or CD3<sup>neg</sup>NK1.1<sup>pos</sup>NKp46<sup>pos</sup> NK cell population.</p></section><section id="s2-5"><h3 class="pmc_sec_title">Immunophenotyping by flow cytometry</h3>
<p>Single cell suspensions were generated from spleen and tumor-draining lymph nodes by mechanical dissociation using a 100 µm cell strainer. Tumor samples were minced in a digestion enzyme mix (RPMI-1640 supplemented with 0.4 mg/mL collagenase P (Roche) and 0.1 mg/mL DNase I (Roche)). After incubation for 30 min at 37°C, the tumor cell suspension was filtered through a 70 µm cell strainer and washed two times with PBS supplemented with 2% FCS and 5 mM EDTA. For whole blood, erythrocyte lysis was carried out after surface staining by using Pharm Lyse Lysing buffer (BD Biosciences, San Jose, California, USA).</p>
<p>For the detection of HPV E7 (E7)-specific or VSV-GP nucleoprotein (N)-specific CD8+ T cells, samples were stained with fluorescently labeled peptide-MHC tetramers (H-2Db RAHYNIVTF HPV16 E7-APC, MBL) or multimers (H-2Kb RGYVYQGL VSV-NP-PE-tetramer and VSV-NP-APC-dextramer, Immudex) for 20 min at 37°C. Subsequently, surface staining was carried out for 20 min at 4°C with the following antibodies: CD43-FITC (clone 1B11, BD Biosciences), CD3e-PE (clone 145–2 C11, BD Biosciences), CD3-BUV395 (clone 145–2 C11, BD Bioscience), CD127-BV711 (clone SB/199, BD Bioscience), CD62L-APC-Cy7 (clone MEL-14, BD Bioscience), CD45-PerCP (clone 30-F11, Miltenyi), CD27-PerCP-Cy5.5 (clone LG.3A10, BD Biosciences), KLRG1-PE-Cy7 (clone 2F1, BioLegend), CD8-BV421 (clone 53–6.7, BD Biosciences), CX3CR1-BV510 (clone Z8-50, BD Biosciences), CD44-AF700 (clone IM7, BD Bioscience), NK1.1-APC (clone PK136, BD Biosciences) and NKp46-FITC (CD335, clone REA815, Miltenyi Biotec). Dead cells were stained using LIVE/DEAD Fixable Near-IR or Blue Dead Cell Stain Kit (Thermo Fisher) according to manufacturer’s instructions. Samples were fixed in PBS/1% formaldehyde and analyzed using the FACSCanto II (BD Biosciences) conventional or the Sony ID7000 (Sony Biotechnology) spectral flow cytometers. Data analysis was performed using the FlowJo software (FlowJo LLC, Oregon, USA).</p></section><section id="s2-6"><h3 class="pmc_sec_title">Measuring IFN-γ production and degranulation from spleen and tumor CD8+ T cells</h3>
<p>Single-cell suspensions from spleen and tumor tissues were generated as described above for immunophenotyping by flow cytometry. 10<sup>6</sup> tumor cells or 2×10<sup>5</sup> spleen cells were seeded into 96-wells U-bottom plates and cultured in the presence or absence of 2 µg/mL viral N-derived (RGYVYQGL) or E7-derived (RAHYNIVTF) peptides for 3.5 hours. After 1 hour of incubation, GolgiStop (BD Bioscience) was added according to the manufacturer’s instruction. During this incubation period BV-786 labeled CD107a was present in order to detect degranulation. Following incubation, surface staining was carried out for 20 min at 4°C with the following antibodies: CD43-FITC (clone 1B11, BD Biosciences), CD3-BUV395 (clone 145–2 C11, BD Bioscience), CD62L-APC-Cy7 (clone MEL-14, BD Bioscience), CD45-RB613 (clone 30-F11, Miltenyi), CD27-PerCP-Cy5.5 (clone LG.3A10, BD Biosciences), KLRG1-PE-Cy7 (clone 2F1, BioLegend), CD8-BV421 (clone 53–6.7, BD Biosciences), and CD44-AF700 (clone IM7, BD Bioscience). Dead cells were stained using LIVE/DEAD Fixable Blue Dead Cell Stain Kit (Thermo Fisher) according to manufacturer’s instructions. After permeabilization, cells were stained with a PE-labeled IFN-γ antibody (clone XMG1.2, BD Bioscience). Samples were analyzed using the Sony ID7000 (Sony Biotechnology) spectral flow cytometer. Data analysis was performed using the FlowJo software (FlowJo, Oregon, USA). In addition, IFN-producing cells were measured using the ELISpot Plus: Mouse IFN-γ (ALP) kit (MabTech, Germany) following ex vivo stimulation of spleen cells. Briefly, 10<sup>5</sup> spleen cells were stimulated with 2 µg/mL N or E7 peptides for 20 hours in 96-well Enzyme-Linked Immunospot (ELISpot) plates, and IFN-γ-producing cells were stained according to the manufacturer’s instructions.</p></section><section id="s2-7"><h3 class="pmc_sec_title">Quantification of cytokines and chemokines</h3>
<p>Tumors were collected and digested in ProcartaPlex Cell Lysis Buffer (Invitrogen, USA) substituted with 1 mM phenylmethanesulfonylfluoride protease inhibitor (Boston Bioproducts, USA) using the gentleMACS dissociator (Miltenyi Biotec, Germany) according to manufacturer’s instructions. Plasma and tumor lysates were stored at −80°C until use. The protein concentration of tumor lysates was measured using the Bio-Rad DC Protein Assay Kit I (Bio-Rad Laboratories, USA) according to manufacturer’s instructions to ensure equal protein concentration across all samples. Cytokines and chemokines were determined using multiplex bead-based immunoassay LEGENDplex Mouse Anti-Virus Response Panel (13-plex) (BioLegend, San Diego, California, USA) according to manufacturer’s instructions. Data were analyzed using LEGENDplex Cloud-based Data Analysis Software (BioLegend).</p></section><section id="s2-8"><h3 class="pmc_sec_title">In vivo bioluminescence imaging</h3>
<p>For monitoring virus replication in tumor tissues in vivo, tumor-bearing mice were treated intravenously with 1×10<sup>7</sup> TCID<sub>50</sub> VSV-GP-Luc.<a href="#R3" class="usa-link" aria-describedby="R3"><sup>3</sup></a> For luciferase imaging, mice received intraperitoneal injections of 150 mg/kg D-luciferin (D-luciferin potassium salt, in vivo imaging solution at 15 mg/mL) in D-PBS 15 min prior to measurements using a charge-coupled device camera (PhotonIMAGER Optima, Biospace Lab, France). Exposure times were adapted to the amount of luciferase activity. Images were analyzed using manually defined regions of interest using M3Vision image analysis software (Biospace Lab, France). Bioluminescence was expressed as photon flux (photons s<sup>−1</sup>sr<sup>−1</sup>) in the region of interest. Background radiance was defined from a region of interest drawn over background.</p></section><section id="s2-9"><h3 class="pmc_sec_title">Data analysis</h3>
<p>Statistics were calculated using GraphPad Prism software (V.10, GraphPad Software, La Jolla, California, USA). Used statistical tests included unpaired two-tailed t-test, one-way analysis of variance (ANOVA) with Tukey’s multiple comparison, two-way ANOVA test with Sidak’s multiple comparison, Kruskal-Wallis test and log-rank test as indicated in the figure legend. Statistically significant differences were encoded as follows: *p&lt;0.05; **p&lt;0.01; ***p&lt;0.001; ****p&lt;0.0001; and ns for not significant.</p></section></section><section id="s3"><h2 class="pmc_sec_title">Results</h2>
<section id="s3-1"><h3 class="pmc_sec_title">Defective type I IFN responsiveness in subcutaneous TC-1 model supports the therapeutic efficacy of oncolytic VSV-GP encoding IL-12</h3>
<p>Transformed murine lung epithelial cells TC-1 expressing HPV-derived oncoproteins are susceptible to VSV-GP infection in vitro; however, subcutaneous TC-1 tumors are weakly susceptible to VSV-GP infection in the mouse.<a href="#R4" class="usa-link" aria-describedby="R4"><sup>4</sup></a> The absence of bioluminescence signal after treatment of TC-1 tumor-bearing mice with VSV-GP expressing firefly luciferase (VSV-GP-Luc) indicated weak or no VSV-GP replication in the tumors (<a href="#SP1" class="usa-link">online supplemental figure S1A</a>). When mixing TC-1 cells used for tumor implantation with IFNαR1-deficient TC-1 cells (TC-1<em>ifnar1<sup>–/–</sup></em>) in either 80:20 or 20:80 proportions bioluminescent signal was clearly detectable 24 hours after VSV-GP-Luc infection. Signal intensity increased at least up to day 4 and was still detectable at day 7 post infection indicating a persistent replication of VSV-GP in this mixed tumor setting (<a href="#SP1" class="usa-link">online supplemental figure S1A</a>). In vitro infection with VSV-GP-GFP in a 50:50 mixture of TC-1 cells expressing the fluorochrome cerulean and non-labeled TC-1<em>ifnar1<sup>−/−</sup></em> cells, with or without preincubation of exogenous IFN-α, revealed that type I IFNs potentially induced in mice on VSV-GP infections can protect TC-1 cells but not TC-1<em>ifnar1<sup>−/−</sup></em> cells from infection (<a href="#SP1" class="usa-link">online supplemental methods</a> and <a href="#SP1" class="usa-link">online supplemental figure S1B</a>). This suggests a preferential infection of IFNαR1-deficient TC-1 cells in vitro. Further experiments showed that both TC-1 and TC-1<em>ifnar1<sup>−/−</sup></em> cells grew equally after subcutaneous tumor implantation, and VSV-GP treatment specifically reduced the TC-1<em>ifnar1<sup>−/−</sup></em> component in the mixed tumor setting, indicating a preferential infection and oncolytic activity of VSV-GP against IFNαR1-deficient cells in vivo (<a href="#SP1" class="usa-link">online supplemental figure S1C</a>). These results supported the suitability of the mixed tumor model to achieve prolonged replication and transgene expression of the type I IFN-sensitive oncolytic VSV-GP and therefore provide the possibility to evaluate the therapeutic efficacy of the VSV-GP encoding murine IL-12 (VSV-GP-IL12) as an immunomodulatory cargo. Moreover, this mixed model more closely resembles naturally occurring tumors that harbor cells which have lost responsiveness to type I IFNs.<a href="#R28" class="usa-link" aria-describedby="R28">28</a>,<a href="#R30" class="usa-link" aria-describedby="R30">30</a> In subsequent experiments, TC-1, TC-1:TC-1<em>ifnar1<sup>−/−</sup></em> 80:20 or 20:80 mixed tumor bearing mice were treated intravenously with 10<sup>7</sup> TCID<sub>50</sub> of VSV-GP or VSV-GP-IL12. Single systemic VSV-GP or VSV-GP-IL12 injections into the mice with TC-1 tumors showed no effect on tumor growth and survival in comparison to the PBS-treated control mice (<a href="#F1" class="usa-link">figure 1</a> and <a href="#SP1" class="usa-link">online supplemental figure S2</a>). In contrast, treatment with VSV-GP and VSV-GP-IL12 in both 80:20 and 20:80 mixed TC-1 tumor settings delayed tumor growth, whereby VSV-GP-IL12 was more effective than VSV-GP (<a href="#F1" class="usa-link">figure 1</a> and <a href="#SP1" class="usa-link">online supplemental figure S2</a>). This was evident from the non-overlapping 95% CI values of the mean tumor growth curves, indicating a statistically significant difference between the treatments, particularly in the 80:20 setting (<a href="#F1" class="usa-link">figure 1</a>). Median survival of VSV-GP-IL12 treated mice increased to 37.5 days (80:20) and 52.5 days (20:80), in comparison to 22 days (80:20) and 29 days (20:80) for VSV-GP, respectively (<a href="#SP1" class="usa-link">online supplemental figure S2</a>). Thus, both 80:20 and 20:80 mixed TC-1 tumor settings were suitable to investigate the mechanisms of improved therapeutic efficacy of VSV-GP-IL12 over VSV-GP. Since the oncolytic component is expected to be less relevant in the 80:20 setting, and differences in the therapeutic efficacy regarding early tumor control between VSV-GP and VSV-GP-IL12 appeared slightly better compared with the 20:80 setting (<a href="#F1" class="usa-link">figure 1</a>), we selected the 80:20 condition for further experiments. Given that the difference in the therapeutic outcome between VSV-GP and VSV-GP-IL12 treatment is likely due to the immunomodulatory cargo, subsequent experiments focused on immune cell populations relevant to tumor control.</p>
<figure class="fig xbox font-sm" id="F1"><h4 class="obj_head">Figure 1. Defective type I IFN responsiveness in TC-1:TC-1<em>ifnar1</em><sup>−/−</sup> mixed tumor model improves the tumor control by VSV-GP encoding IL-12. C57BL/6J mice were s.c. injected with TC-1 wild-type (TC-1) or mixed TC-1 and IFNαR1-deficient TC-1 cells (TC-1<em>ifnar1<sup>−/−</sup></em>) in an 80:20 or 20:80 ratio (TC-1:TC-1<em>ifnar1</em><sup>−/−</sup> 80:20 and TC-1:TC-1<em>ifnar1</em><sup>−/−</sup> 20:80, respectively). Mice were treated at day 11 (dotted line) intravenous either with PBS (control) or 1×10<sup>7</sup> TCID<sub>50</sub> VSV-GP (GP) or VSV-GP-IL-12 (GP-IL-12). Mean (±95% CI) tumor growth curves of PBS, VSV-GP-treated and VSV-GP-IL-12-treated tumor-bearing mice (8–10 mice per group) are shown. Non-overlapping 95% CI values of the mean tumor growth curves indicate a statistically significant difference between the treatments, particularly in the 80:20 setting. GP, glycoprotein; IFN, interferon; IL, interleukin; PBS, phosphate-buffered saline; s.c., subcutaneous; VSV, vesicular stomatitis virus.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12366581_jitc-13-8-g001.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0382/12366581/caf01a091932/jitc-13-8-g001.jpg" loading="lazy" height="185" width="735" alt="Figure 1"></a></p>
<div class="p text-right font-secondary"><a href="figure/F1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></figure></section><section id="s3-2"><h3 class="pmc_sec_title">Significant differences in activation and phenotype of NK and CD8+ T-cell responses between VSV-GP and VSV-GP-IL12 treatment</h3>
<p>In the next set of experiments, 80:20 mixed TC-1 tumor-bearing mice were treated with VSV-GP and VSV-GP-IL12 to study the activation and phenotype of NK cells and CD8+ T cells. Both cell types are crucial for antitumor immunity. NK cells were determined as CD3/CD19 negative NK1.1 (CD161) and NKp46 (CD335) positive cells and showed a rapid drop in frequencies and numbers in peripheral blood on OV treatment (<a href="#F2" class="usa-link">figure 2A</a>). Whereas NK cell counts normalized after 3 days following VSV-GP injection, VSV-GP-IL12 treatment resulted in a prolonged reduction of NK cells observed until at least 7 days post treatment in the periphery (<a href="#F2" class="usa-link">figure 2A</a>). This decline could result from a strong NK cell activation by VSV-GP-IL12 as we found significantly higher proportion of KLRG1+ activated cells within the NK cell population when compared with VSV-GP treatment (<a href="#F2" class="usa-link">figure 2A</a>). Although VSV-GP-IL12 induced significantly higher proportions of activated KLRG1+ NK cells, total numbers of activated NK cells in blood remained significantly lower compared with VSV-GP treatment (<a href="#F2" class="usa-link">figure 2A</a>). This suggests that VSV-GP-IL12 induces strong activation of NK cells, which in turn most likely leave the blood stream and home to peripheral organs or the tumor.</p>
<figure class="fig xbox font-sm" id="F2"><h4 class="obj_head">Figure 2. Different phenotypic signatures of activated NK and CD8+T cells between VSV-GP and VSV-GP-IL-12. Mixed TC-1:TC-1<em>ifnar1<sup>−/−</sup></em> (80:20) cells were implanted s.c. on the right flank of C57BL/6J mice. Mice were treated when the tumor reached a volume of 0.05 cm<sup>3</sup> intravenous with either phosphate-buffered saline (control) or 1×10<sup>7</sup> TCID<sub>50</sub> VSV-GP or VSV-GP-IL-12. Kinetics of NK cell response in blood (<strong>A</strong>) analyzed by frequencies and total numbers (in 1 mL blood) of NK cells (CD3<sup>neg</sup> NK1.1<sup>pos</sup>CD335<sup>pos</sup>) and activated NK cells (KLRG1<sup>pos</sup> NK cells). CD8+T cell response (<strong>B</strong>) on total CD8+T cells based on activation markers (CD27, CD43, and KLRG1) was analyzed by flow cytometry in the blood at indicated time points. Values are expressed as mean±SD (n=3). Data were analyzed by using two-way analysis of variance followed by Šídák’s multiple comparisons (*p&lt;0.05; **p&lt;0.01; ***p&lt;0.001; ****p&lt;0.0001). Phenotypic signature of CD8+T cells (<strong>C</strong>) in the blood at 7 and 14 days, and in the spleen, tdLN and tumors harvested at 15 days post treatment. Figure shows frequencies of CD8+T cell subpopulations based on their expression of CD27, CD43 and KLRG1 measured by flow cytometry. Data show mean values (n=7–10) derived from two independent experiments. Detailed statistical analysis of the different populations comparing control, VSV-GP and VSV-GP-IL-12 treatments can be found in <a href="#SP1" class="usa-link">online supplemental table 1 and 2</a>. dLN, draining lymph node; GP, glycoprotein; IL, interleukin; NK, natural killer; s.c., subcutaneous; VSV, vesicular stomatitis virus.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12366581_jitc-13-8-g002.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0382/12366581/6d9c6e183d53/jitc-13-8-g002.jpg" loading="lazy" height="1168" width="735" alt="Figure 2"></a></p>
<div class="p text-right font-secondary"><a href="figure/F2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></figure><p>In contrast to innate NK cells responding rapidly to virus treatment, activation of CD8+ T cell responses could first be detected at day 4–5 following virus treatment (<a href="#F2" class="usa-link">figure 2B</a>). To define the subsets of activated CD8+ T cells, we dissected CD8+ T cells based on the expression of CD27, activation-associated glycoform of early activation marker CD43, and KLRG1. KLRG1 is often used to identify actively responding effector CD8+ T cells, while CD43 plays a role in CD8+ T cell activation, differentiation and function with its activation-associated glycoform serving as marker for effector CD8+ T cells.<a href="#R31" class="usa-link" aria-describedby="R31"><sup>31 32</sup></a> In contrast, the loss of CD27 is linked to the acquisition of effector functions in CD8+ T cells.<a href="#R33" class="usa-link" aria-describedby="R33"><sup>33</sup></a> Total CD8+ T cells within live CD45+cells were gated, and fluorescence minus one (FMO) controls were used to set gates for CD27+, CD43+ or KLRG1+ populations (<a href="#SP1" class="usa-link">online supplemental figure S3</a>). Frequencies of CD43-expressing CD8+ T cells started to increase from day 3 after both VSV-GP and VSV-GP-IL12 injections indicating an activation of CD8+ T cells. At day 7 post treatment both the frequencies of total and CD43 positive CD8+ T cells were significantly higher after VSV-GP-IL12 in comparison to VSV-GP treatment (<a href="#F2" class="usa-link">figure 2B</a>). Interestingly, VSV-GP-IL12 induced significantly higher frequencies of KLRG1 positive CD8+ T cells compared with VSV-GP treatment (<a href="#F2" class="usa-link">figure 2B</a>). In contrast, CD27 expression on CD8+ T cells started to decline day 5 after VSV-GP-IL12 treatment, resulting in significantly lower proportions of CD8+ T cells expressing CD27 on day 7 post VSV-GP-IL12 treatment when compared with VSV-GP (<a href="#F2" class="usa-link">figure 2B</a>).</p>
<p>We next investigated the co-expression of the above-mentioned CD8+ T cell markers in peripheral blood after 7 and 14 days post VSV-GP and VSV-GP-IL12 treatment in 80:20 mixed TC-1 tumor-bearing mice. Single-marker positive populations for CD27, CD43 and KLRG1 in CD8+ T cells were defined using FMO controls, and a Boolean gating strategy in FlowJo software was applied to automatically generate all possible marker combinations. The data were then visualized as color-coded stacked bar graphs representing the distribution of different marker co-expressing populations (<a href="#F2" class="usa-link">figure 2C</a>). A detailed statistical analysis of the different populations comparing control, VSV-GP and VSV-GP-IL12 treatments can be found in <a href="#SP1" class="usa-link">online supplemental table 1 and 2</a>. After both treatment regimens, we found a strong reduction of CD27<sup>pos</sup> naïve CD8+ T cells expressing neither CD43 nor KLRG1 (CD27<sup>pos</sup>CD43<sup>neg</sup>KLRG1<sup>neg</sup>), suggesting a potent activation on day 7 and, to a lesser extent, also on day 14 after treatment (<a href="#F2" class="usa-link">figure 2C</a>). Interestingly, VSV-GP induced dominantly CD27<sup>pos</sup>CD43<sup>pos</sup>KLRG1<sup>neg</sup> CD8+ T cells, whereas after VSV-GP-IL12 injection CD27<sup>neg</sup>CD43<sup>pos</sup>KLRG1<sup>pos</sup> cells represented the most prominent population at day 7 post treatment (<a href="#F2" class="usa-link">figure 2C</a> and <a href="#SP1" class="usa-link">online supplemental figure S4A</a>). After 14 days of virus treatment, the activation of CD8+ T cells subsided and started to contract, as indicated by the increasing proportion of CD27<sup>pos</sup>CD43<sup>neg</sup>KLRG1<sup>neg</sup> cells. Importantly, at 14 days following VSV-GP-IL12 treatment, we found higher frequencies of KLRG1<sup>pos</sup> CD8+ T cells expressing neither CD27 nor CD43 (CD27<sup>neg</sup>CD43<sup>neg</sup>KLRG1<sup>pos</sup>) (<a href="#F2" class="usa-link">figure 2C</a> and <a href="#SP1" class="usa-link">online supplemental figure S4A</a>), a phenotype that was previously described for LLECs induced on LCMV infection.<a href="#R21" class="usa-link" aria-describedby="R21"><sup>21 22</sup></a> Importantly, the differences in CD8+ T cell phenotype in the blood and spleen were reflected in that found in the tumors on days 10 and 15 after both VSV-GP and VSV-GP-IL12 treatment (<a href="#SP1" class="usa-link">online supplemental figure S4B</a> and <a href="#F2" class="usa-link">figure 2C</a>, respectively). Of note, the higher proportion of TC-1<em>ifnar1<sup>−/−</sup></em> cells in the mixed TC-1 model, led to higher frequencies of CD8+ T cells displaying the CD27<sup>neg</sup>CD43<sup>neg</sup>KLRG1<sup>pos</sup> phenotype at day 9 post treatment, which was likely due to higher virus replication and IL-12 production (<a href="#SP1" class="usa-link">online supplemental figure S5</a>).</p></section><section id="s3-3"><h3 class="pmc_sec_title">IL-12 promotes the generation of specific CD8+ T cells with a CD27<sup>neg</sup>CD43<sup>neg</sup>KLRG1<sup>pos</sup> phenotype</h3>
<p>VSV-GP treatment of mice has been shown to induce strong antiviral CD8+ T cells responses,<a href="#R34" class="usa-link" aria-describedby="R34"><sup>34</sup></a> which on one hand controls viral spread but might also contribute to tumor control by killing virus-infected tumor cells. In addition, oncolytic activity has also been demonstrated to promote tumor-specific CD8+ T cells.<a href="#R10" class="usa-link" aria-describedby="R10">1034</a>,<a href="#R36" class="usa-link" aria-describedby="R36">36</a> Thus, we next investigated the induction and the phenotype of VSV-GP N-specific as well as tumor-related HPV E7-specific responses 7 and 14 days post VSV-GP and VSV-GP-IL12 injections of 80:20 mixed TC-1 tumor-bearing mice.</p>
<p>As expected, both treatment regimens induced antiviral CD8+ T cell responses as indicated by the presence of N-specific CD8+ T cells in the peripheral blood on day 7 (<a href="#F3" class="usa-link">figure 3A</a>). At day 14 after treatment, N-specific response decreased compared with day 7, but was still detectable (<a href="#F3" class="usa-link">figure 3A</a>). Although the frequencies of N-specific CD8+ T cells were not significantly different between VSV-GP and VSV-GP-IL12 treated animals (<a href="#F3" class="usa-link">figure 3A</a>), we found noticeable differences with respect to VSV-N specific CD8+ T cell phenotypes (<a href="#F3" class="usa-link">figure 3B and C</a>). Whereas N-specific CD8+ T cells induced by VSV-GP showed significantly higher frequencies of both CD27<sup>pos</sup> and CD43<sup>pos</sup> cells, VSV-GP-IL12 treatment resulted in a virus-specific response with significantly higher proportion of KLRG1<sup>pos</sup> CD8+ T cells at day 14 post treatment (<a href="#F3" class="usa-link">figure 3B</a> and <a href="#SP1" class="usa-link">online supplemental figure S3</a>). This resulted predominantly in virus-specific CD8+ T cells characterized by a CD27<sup>pos</sup>CD43<sup>pos</sup>KLRG1<sup>neg</sup> phenotypic signature when mice were treated with VSV-GP only, whereas VSV-GP-IL12 promoted virus-specific CD8+ T cell response with a prominent presence of the CD27<sup>neg</sup>CD43<sup>neg</sup>KLRG1<sup>pos</sup> phenotype (<a href="#F3" class="usa-link">figure 3C</a>). Detailed statistical analysis of the above populations comparing VSV-GP and VSV-GP-IL12 treatments can be found in <a href="#SP1" class="usa-link">online supplemental table 3</a>.</p>
<figure class="fig xbox font-sm" id="F3"><h4 class="obj_head">Figure 3. VSV-GP-IL12 promotes the generation of N-specific and E7-specific CD8+ T cells with a phenotypic signature characterized by CD27<sup>neg</sup>CD43<sup>neg</sup>KLRG1<sup>pos</sup> CD8+ T cells. C57BL/6J mice implanted with mixed TC-1:TC-1<em>ifnar1<sup>−/−</sup></em> (80:20) cells were treated at day 11 intravenously with phosphate-buffered saline (control), 1×10<sup>7</sup> TCID<sub>50</sub> VSV-GP (GP) or VSV-GP-IL12 (GP-IL12) and blood was taken 7 and 14 days post treatment (dpt). Frequency of N-specific (antiviral) CD8+T cells (Ntet+) at 7 and 14 dpt (<strong>A</strong>) and expression of activation markers CD27, CD43 and KLRG1 on N-specific CD8+ T cells at 14 dpt (<strong>B</strong>) are shown. (<strong>C</strong>) Phenotypic signature of N-specific antiviral CD8+ T cells based on the expression of CD27, CD43 and KLRG1 in VSV-GP (GP) or VSV-GP-IL12 (GP-IL12) treated mice at 14 dpt. (<strong>D</strong>) Percentage of E7-specific (tumor-specific) CD8+ T cells (E7tet+) at 7 and 14 dpt. (<strong>E</strong>) Phenotypic signature of E7-tetramer positive CD8+ T cells based on the expression of CD27, CD43 and KLRG1 at 14 dpt (analyzed from mice over the detection limit set at 0.1% E7tet+ cells; n=4 for control, n=7 for VSV-GP, and n=11 for VSV-GP-IL12 groups). Data were analyzed using non-parametric analysis of variance using Kruskal-Wallis test followed by Dunn’s multiple comparisons for <strong>A</strong> and <strong>D</strong>, and unpaired, two-tailed Mann-Whitney test for <strong>B</strong> (*p&lt;0.05; **p&lt;0.01; ***p&lt;0.001; ****p&lt;0.0001). Dotted line in (<strong>A</strong>) and (<strong>D</strong>) represents threshold for positivity set for the detection of specific CD8+ T cell response. Results in <strong>A</strong> and <strong>D</strong> are derived from n=14–18 mice for 7 dpt (three independent experiments) and n=15–22 for 14 dpt (from three independent experiments). Results in <strong>B</strong> are derived from n=17 for 14 dpt (from three independent experiments) and in <strong>C</strong> are derived from n=7 for 14 dpt (from one experiment). Detailed statistical analysis of the different populations comparing control, VSV-GP and VSV-GP-IL12 treatments in <strong>figures 3C and 3E</strong> can be found in <a href="#SP1" class="usa-link">online supplemental table 3 and 4</a>, respectively. GP, glycoprotein; IL, interleukin; VSV, vesicular stomatitis virus.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12366581_jitc-13-8-g003.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0382/12366581/727b9a0cf212/jitc-13-8-g003.jpg" loading="lazy" height="772" width="735" alt="Figure 3"></a></p>
<div class="p text-right font-secondary"><a href="figure/F3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></figure><p>We then conducted a deeper analysis of total and N-specific CD8+ T cell subsets using the markers CD44, CD62L, KLRG1, CD43, CD27 and CD127 measured by flow cytometry in blood samples taken 14 days post treatment (<a href="#F4" class="usa-link">figure 4</a>). Of note, there was no significant change in the proportions of naïve CD62L<sup>pos</sup>CD44<sup>low</sup>, CD62L<sup>neg</sup>CD44<sup>pos</sup> CD8+ T effector/effector memory (TE/TEM) and CD62L<sup>high</sup>CD44<sup>pos</sup> CD8+ T central memory (TCM) populations between VSV-GP-treated and VSV-GP-IL12-treated animals (<a href="#F4" class="usa-link">figure 4A</a>). The induction of N-specific antiviral CD8+ T cells was similar between VSV-GP and VSV-GP-IL12 treatments (<a href="#F4" class="usa-link">figure 4B</a>). The vast majority of N-specific CD8+ T cells after both VSV-GP and VSV-GP-IL12 injections exhibited a TE/TEM phenotype, whereas a minority of N-specific cells displayed a TCM phenotype (<a href="#F4" class="usa-link">figure 4C</a>). As expected, CD8+ T cells expressing the activation markers CD43 and KLRG1 were mainly found within the TE/TEM CD8+ T cell population. Consistent with our data above concerning the CD43 and KLRG1 expression, in TE/TEM cells VSV-GP induced a heterogeneous expression pattern equally contributed by CD43<sup>pos</sup>KLRG1<sup>neg</sup> (blue), CD43<sup>pos</sup>KLRG1<sup>pos</sup> (purple) and CD43<sup>neg</sup>KLRG1<sup>pos</sup> (red) among both total and N-specific CD8+ T cells (<a href="#F4" class="usa-link">figure 4D</a> and <a href="#SP1" class="usa-link">online supplemental figure S6A</a>). In contrast, the majority of TE/TEMs displayed a CD43<sup>neg</sup>KLRG1<sup>pos</sup> (red) phenotype of both total and N-specific CD8+T cells after VSV-GP-IL12 treatment (<a href="#F4" class="usa-link">figure 4D</a> and <a href="#SP1" class="usa-link">online supplemental figure S6A</a>). Detailed statistical analysis of the above populations comparing VSV-GP and VSV-GP-IL12 treatments can be found in <a href="#SP1" class="usa-link">online supplemental table 4 and 5</a>. Whereas CD43<sup>pos</sup>KLRG1<sup>neg</sup> (blue) and CD43<sup>neg</sup>KLRG1<sup>neg</sup> (black) N-specific TE/TEM cells exhibited higher expression levels of CD27 and CD127 (<a href="#F4" class="usa-link">figure 4E</a>), CD43<sup>neg</sup>KLRG1<sup>pos</sup> (red) TE/TEMs had the lowest expression of both CD27 and CD127 (<a href="#F4" class="usa-link">figure 4E</a>), corresponding to the phenotype previously described for LLECs<a href="#R21" class="usa-link" aria-describedby="R21"><sup>21 22</sup></a> or terminally differentiated effector memory cells (terminal-TEM).<a href="#R23" class="usa-link" aria-describedby="R23"><sup>23</sup></a> Given that both CD43<sup>neg</sup>KLRG1<sup>pos</sup> (red) and CD43<sup>pos</sup>KLRG1<sup>pos</sup> (purple) TE/TEMs can traditionally be classified as short-lived effector cells (SLEC) based on the expression of KLRG1 and CD127 (<a href="#F4" class="usa-link">figure 4E</a>), we propose that the absence of CD43 may not only define LLECs but could also be a useful marker to distinguish developing LLECs within the SLEC population.</p>
<figure class="fig xbox font-sm" id="F4"><h4 class="obj_head">Figure 4. Phenotypic analysis of total and N-specific blood CD8+ T cells. Mixed TC-1:TC-1<em>ifnar1<sup>−/−</sup></em> (80:20) tumor-bearing mice were treated with phosphate-buffered saline (control; n=5), VSV-GP (n=5) or VSV-GP-IL12 (n=5) and peripheral blood was analyzed 14 days post treatment for CD44, CD62L, KLRG1, CD43, CD27 and CD127 expression by flow cytometry. N-specific CD8+ T cells (Ntet+) were determined by tetramer staining. (<strong>A</strong>) The gating strategy is shown for one representative mouse out of five treated with VSV-GP-IL12. CD8+ T cells (CD3×CD8 plot) were derived from gating on lymphocytes&gt;singlets&gt;living CD45 positive cells. Using CD44 and CD62L (CD44×CD62L plot) as markers, total CD8+ T and N-tetramer positive (Ntet+) virus-specific cells were further divided into CD44<sup>low</sup>CD62L<sup>+</sup> naïve, CD44<sup>high</sup>CD62L<sup>+</sup> central memory (TCM), and CD44<sup>+</sup>CD62L<sup>−</sup> effector/effector-memory (TE/TEM) populations. Within total naïve, TCM and TE/TEM populations, as well as in N-specific TE/TEMs, CD43 and KLRG1 (CD43×KLRG1 dot plots) expression patterns defined subpopulations of CD43<sup>neg</sup>KLRG1<sup>neg</sup> (black), CD43<sup>pos</sup>KLRG1<sup>neg</sup> (blue), CD43<sup>pos</sup>KLRG1<sup>pos</sup> (purple) and CD43<sup>pos</sup>KLRG1<sup>pos</sup> (red) cells. (<strong>B</strong>) There was no significant difference in the frequencies of Ntet+ virus-specific CD8+ T cells induced by VSV-GP and VSV-GP-IL12 treatments. Statistical analysis was performed using the non-parametric Kruskal-Wallis test with Dunn’s multiple comparisons (*p&lt;0.05; ns, not significant). (<strong>C</strong>) The gating on naïve, TCM, and TE/TEM populations revealed that the vast majority of N-specific cells displayed a TE/TEM phenotype. The numbers represent the mean percentage of the corresponding population within Ntet+ CD8+ T cells (n=5 per treatment groups). (<strong>D</strong>) 5000 CD8+T cells per treated animal were analyzed and the mean percentage of CD43<sup>pos</sup>KLRG1<sup>neg</sup> (blue), CD43<sup>pos</sup>KLRG1<sup>pos</sup> (purple), CD43<sup>pos</sup>KLRG1<sup>pos</sup> (red) and CD43<sup>neg</sup>KLRG1<sup>neg</sup> (black) subpopulations within total naïve, TCM and TE/TEM as well as in N-specific (Ntet+) TE/TEMs after VSV-GP and VSV-GP-IL12 treatments are shown. (<strong>E</strong>) Ntet+ cells from 5000 CD8+ T cells per treated animal were concatenated and are presented in color-coded CD43×KLRG1dot plots. The expression of CD27 and CD127 in these CD43/KLRG1 subpopulations is shown in color-coded histograms. Numbers within the histograms represent mean fluorescence intensities to the respective peak (n.a.; not applicable due to low cell numbers). Color-coded CD43/KLRG1 subpopulations were also divided into KLRG1<sup>neg</sup>CD127<sup>low</sup> early effector cell (EEC), KLRG1<sup>pos</sup>CD127<sup>low</sup> short-lived effector cell (SLEC), KLRG1<sup>pos</sup>CD127<sup>pos</sup> double positive (DP), and KLRG1<sup>neg</sup>CD127<sup>pos</sup> memory precursor cell (MPEC) populations based on the expression of KLRG1 and CD127. GP, glycoprotein; IL, interleukin; VSV, vesicular stomatitis virus.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12366581_jitc-13-8-g004.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0382/12366581/9ce60ce67e6e/jitc-13-8-g004.jpg" loading="lazy" height="1334" width="735" alt="Figure 4"></a></p>
<div class="p text-right font-secondary"><a href="figure/F4/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></figure><p>To study the induction of antitumor responses, we investigated the generation of CD8+ T cells against the HPV16-derived immunodominant epitope of E7<sup>49–57</sup> (RAHYNIVTF).<a href="#R37" class="usa-link" aria-describedby="R37"><sup>37</sup></a> We found that in 80:20 mixed TC-1 tumor-bearing mice E7-specific response can be generated spontaneously even in PBS-treated control mice. Although we found slightly more mice with detectable frequencies of E7-specific responses after both VSV-GP and VSV-GP-IL12 injections, neither treatment resulted in a significant difference of E7-specific CD8+ T cell frequencies on day 14 post treatment (<a href="#F3" class="usa-link">figure 3D</a>). Nevertheless, E7-specific responses were clearly detectable in all animals with long-term survival at day 60 post treatment suggesting that long-term survival is dependent on the presence of E7-specific CD8+ T cells (<a href="#SP1" class="usa-link">online supplemental figure S7</a>). Similar to the antiviral response, if detectable, E7-specific CD8+ T cells from control and VSV-GP-treated animals revealed a predominant CD27<sup>pos</sup>CD43<sup>pos</sup>KLRG1<sup>neg</sup> phenotype, whereas VSV-GP-IL12 promoted E7-specific CD8+T cell response showed a CD27<sup>neg</sup>CD43<sup>pos</sup>KLRG1<sup>pos</sup> or CD27<sup>neg</sup>CD43<sup>neg</sup>KLRG1<sup>pos</sup> phenotypic signature (<a href="#F3" class="usa-link">figure 3E</a> and <a href="#SP1" class="usa-link">online supplemental figure S6B</a>). Importantly, the majority of E7-specific CD8+ T cells also displayed a CD27<sup>neg</sup>CD43<sup>neg</sup>KLRG1<sup>pos</sup> phenotype in long-term surviving animals at 60 days post VSV-GP-IL12 treatment (<a href="#SP1" class="usa-link">online supplemental figure S7</a>).</p></section><section id="s3-4"><h3 class="pmc_sec_title">Induction of different expression profiles of plasma and intratumoral cytokines/chemokines by VSV-GP and VSV-GP-IL12</h3>
<p>Cytokines and chemokines play a critical role in the regulation of the TME, thus it is also important to understand how cytokines/chemokines are modulated by oncolytic virotherapy especially if OV express immunomodulatory molecules such as IL-12.<a href="#R34" class="usa-link" aria-describedby="R34"><sup>34 38</sup></a> Therefore, we measured pro-inflammatory and anti-inflammatory cytokines/chemokines in plasma and tumor lysates at different time points (0.5, 1, 2, 3, 4 and 7 days) after VSV-GP and VSV-GP-IL12 treatment. As expected, compared with control and VSV-GP-treated mice, VSV-GP-IL12 treatment resulted in higher plasma levels of IL-12, which already peaked 12 hours post treatment, followed with a secondary peak at day 4. 7 days post VSV-GP-IL12 treatment, plasma levels of IL-12 returned to their normal levels found in control animals. In contrast, VSV-GP treatment did not affect IL-12 levels in plasma compared with the control (<a href="#SP1" class="usa-link">online supplemental figure S8A</a>). Importantly, we found significantly higher concentrations of IFN-γ in plasma shortly after VSV-GP-IL12 treatment in comparison to PBS-treated and VSV-GP-treated animals (<a href="#SP1" class="usa-link">online supplemental figure S8</a>). Some cytokines/chemokines like IFN-α, CCL2 and CXCL10 were elevated on both virus treatment, whereby CXCL10 levels were slightly higher after VSV-GP-IL12 injection (<a href="#SP1" class="usa-link">online supplemental figure S8A</a>).</p>
<p>In the tumor lysates, we detected higher levels of IL-12 already 12 hours after VSV-GP-IL12 in comparison to control and VSV-GP, peaking between 2 and 4 days post injections (<a href="#SP1" class="usa-link">online supplemental figure S8B</a>). We also found increased production of IFN-γ within the tumor of VSV-GP-IL12-treated mice compared with control and VSV-GP-treated animals. All the other investigated cytokines/chemokines were only slightly affected by the treatment regimens (<a href="#SP1" class="usa-link">online supplemental figure S8B</a>).</p></section><section id="s3-5"><h3 class="pmc_sec_title">VSV-GP-IL12 treatments triggered IFN-γ production but did not affect the degranulation of spleen and tumor CD8+ T cells compared with VSV-GP</h3>
<p>As IFN-γ production by CD8+T cells has been associated with the therapeutic efficacy of cancer immunotherapies using IL-12 in previous studies,<a href="#R39" class="usa-link" aria-describedby="R39"><sup>39 40</sup></a> we next investigated the functionality of CD8+T cells more closely by measuring IFN-γ production and degranulation of CD8+T cells in spleen (<a href="#SP1" class="usa-link">online supplemental figures S9 and S10</a>) and tumor tissues (<a href="#F5" class="usa-link">figure 5</a>) at 7 and 14 days post VSV-GP and VSV-GP-IL12 treatments. Single-cell suspension from both spleen and tumor tissues was generated, and cells were restimulated ex vivo with either viral N-derived (RGYVYQGL) or E7-derived (RAHYNIVTF) peptides for 3 hours.</p>
<figure class="fig xbox font-sm" id="F5"><h4 class="obj_head">Figure 5. Functional analysis of tumor CD8+ T cells. Mixed TC-1:TC-1<em>ifnar1<sup>−/−</sup></em> (80:20) tumor-bearing mice were treated with VSV-GP or VSV-GP-IL12 and tumor tissues were harvested at day 7 and 14 post treatment (n=4–5 mice). Tumors were enzymatically digested to generate single-cell suspensions. 10<sup>6</sup> tumor cells were stimulated with 2 µg/mL N or E7 peptides for 3 hours. As a control, tumor cells were cultivated without peptides (no stimulation). To determine degranulation, BV786-labeled CD107a antibody was present during the 3 hours incubation. Following incubation, cells were stained for cell surface markers and after permeabilization stained with a PE-labeled IFN-γ antibody. (<strong>A</strong>) The gating strategy is shown for one representative mouse out of five treated with VSV-GP or VSV-GP-IL12. CD8+ T cells (CD3×CD8) were derived from gating on lymphocytes&gt;singlets&gt;living CD45 positive cells. Representative color-coded dot plots show the distribution of CD43<sup>pos</sup>KLRG1<sup>neg</sup> (blue), CD43<sup>pos</sup>KLRG1<sup>pos</sup> (purple), CD43<sup>neg</sup>KLRG1<sup>pos</sup> (red) and CD43<sup>neg</sup>KLRG1<sup>neg</sup> (black) subpopulations within total CD8+ T cells after 7 and 14 dpt. (<strong>B</strong>) Percentage of CD43<sup>pos</sup>KLRG1<sup>neg</sup> (blue), CD43<sup>pos</sup>KLRG1<sup>pos</sup> (purple), CD43<sup>neg</sup>KLRG1<sup>pos</sup> (red) and CD43<sup>neg</sup>KLRG1<sup>neg</sup> (black) subpopulations within total CD8+ T cells after 7 and 14 dpt derived from n=4–5 mice per group. Percentage and mean fluorescence intensities (MFI) of IFN-γ positive tumor CD8+ T cells derived 7 (<strong>C</strong>) and 14 dpt (<strong>D</strong>) with VSV-GP or VSV-GP-IL12 after 3 hours ex vivo stimulation with N or E7 peptides. (<strong>E</strong>) Relative percentage of CD43<sup>pos</sup>KLRG1<sup>neg</sup> (blue), CD43<sup>pos</sup>KLRG1<sup>pos</sup> (purple), CD43<sup>neg</sup>KLRG1<sup>pos</sup> (red) and CD43<sup>neg</sup>KLRG1<sup>neg</sup> (black) subpopulations is shown within IFN-γ positive tumor CD8+ T cells. Data in <strong>E</strong> were analyzed using two-way ANOVA followed by Sidak’s multiple comparisons test. Asterisks indicate significant differences between the corresponding colored populations in the VSV-GP and VSV-GP-IL12 groups (**p&lt;0.01; ***p&lt;0.001; ****p&lt;0.0001; ns, not significant). Representative color-coded dot-plots and histograms from one representative mouse out of five treated with VSV-GP or VSV-GP-IL12 reflecting different CD43/KLRG1 subpopulations (<strong>F and H</strong>) and percentage of CD107a single, CD107a/IFN-γ double and IFN-γ single positive tumor CD8+ T cells (<strong>G and I</strong>) after 3 hours ex vivo peptide stimulation derived from mice at 7 (<strong>F and G</strong>) and 14 days (<strong>H and I</strong>) post VSV-GP or VSV-GP-IL12 treatments. Data were analyzed using two-way ANOVA followed by Sidak’s multiple comparisons for <strong>B</strong>, <strong>C</strong>, <strong>D</strong>, <strong>G</strong> and <strong>I</strong> (*p&lt;0.05; **p&lt;0.01; ***p&lt;0.001; ****p&lt;0.0001). ANOVA, analysis of variance; GP, glycoprotein; IFN, interferon; IL, interleukin; VSV, vesicular stomatitis virus.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12366581_jitc-13-8-g005.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0382/12366581/2e1c8b757b19/jitc-13-8-g005.jpg" loading="lazy" height="898" width="735" alt="Figure 5"></a></p>
<div class="p text-right font-secondary"><a href="figure/F5/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></figure><p>Surface marker staining of both tumor (<a href="#F5" class="usa-link">figure 5A and B</a>) and spleen (<a href="#SP1" class="usa-link">online supplemental figure S9A and B</a>) CD8+ T cells with CD43 and KLRG1 antibodies revealed that, similarly to our data above, at 7 days post treatment (dpt), VSV-GP induced a significantly higher proportion of CD43<sup>pos</sup>KLRG1<sup>neg</sup> (blue) CD8+ T cells, whereas VSV-GP-IL12 treatments induced more double-positive CD43<sup>pos</sup>KLRG1<sup>pos</sup> (purple) CD8+ T cells. In the tumor tissues, at 14 days post-VSV-GP treatments, CD43<sup>pos</sup>KLRG1<sup>neg</sup> (blue) CD8+ T cells remained the predominant population. In contrast, 14 days after VSV-GP-IL12 treatment, CD43<sup>pos</sup>KLRG1<sup>pos</sup> (purple) CD8+ T cells remained prominent, alongside an accumulation of CD43<sup>neg</sup>KLRG1<sup>pos</sup> (red) CD8+ T cells.</p>
<p>Importantly, at both 7 and 14 dpt, a significantly higher percentage of CD8+ T cells positive for IFN-γ was observed after N peptide stimulation in the tumor (<a href="#F5" class="usa-link">figure 5C and D</a>) and spleen (<a href="#SP1" class="usa-link">online supplemental figure S9C and D</a>). Notably, 7 days after VSV-GP-IL12 treatment, a relatively high percentage of CD8+ T cells were positive for IFN-γ without any stimulation, indicating a generally activated state of CD8+ T cells induced by VSV-GP-IL12. Furthermore, the significantly higher median fluorescence intensities (MFIs) of IFN-γ-positive cells at 7 days post VSV-GP-IL12 treatment suggested elevated levels of IFN-γ production by N peptide-stimulated CD8+ T cells. Of note, we found that VSV-GP-IL12 treatments also led to increased IFN-γ production by CD3+CD8+ cells in both the spleen and tumor at 7 dpt, which was not further enhanced by specific peptide stimulation (<a href="#SP1" class="usa-link">online supplemental figure S10</a>).</p>
<p>An increased number of IFN-γ-producing cells in the spleen after VSV-GP-IL12 treatment compared with VSV-GP was confirmed by IFN-γ ELISpot assay after 20 hours of incubation of spleen cells in the presence of N peptides (<a href="#SP1" class="usa-link">online supplemental figure S11</a>). A higher background production of IFN-γ without any stimulation was also observed in spleen cells 7 days post VSV-GP-IL12 treatments in ELISpot. In line with the higher MFIs found in intracellular IFN-γ staining, significantly higher percent area values suggested increased levels of IFN-γ secretion of IFN-γ-producing spleen cells derived from VSV-GP-IL12 treated animals.</p>
<p>Examining CD43 and KLRG1 expression on IFN-γ-producing CD8+ T cells, we found that the majority of IFN-γ-positive CD8+ T cells in both tumor tissues and spleen displayed a CD43<sup>pos</sup>KLRG1<sup>neg</sup> (blue) phenotype after VSV-GP treatments at days 7 and 14 (<a href="#F5" class="usa-link">figure 5E</a> and <a href="#SP1" class="usa-link">online supplemental figure S9E</a>). In contrast, 7 days after VSV-GP-IL12 treatment, IFN-γ producing CD8+ T cells in both tumor and spleen were predominantly CD43<sup>pos</sup>KLRG1<sup>pos</sup> (purple), whereas at 14 days post treatment, IFN-γ producing CD8+ T cells displayed a more heterogeneous phenotype, primarily CD43<sup>pos</sup>KLRG1<sup>pos</sup> (purple) and CD43<sup>neg</sup>KLRG1<sup>pos</sup> cells (red) (<a href="#F5" class="usa-link">figure 5E</a> and <a href="#SP1" class="usa-link">online supplemental figure S9E</a>).</p>
<p>In addition to IFN-γ production, CD8+ T cell degranulation in tumor and spleen was assessed after both VSV-GP and VSV-GP-IL12 treatments by measuring CD107a surface expression (<a href="#F5" class="usa-link">figure 5F–5I</a> and <a href="#SP1" class="usa-link">online supplemental figure S9F-I</a>). In tumors, no significant differences were observed between CD107a single-positive and CD107a/IFN-γ double-positive CD8+ T cells after both treatments. However, IFN-γ-positive cells lacking surface degranulation marker CD107a were significantly elevated after VSV-GP-IL12 (<a href="#F5" class="usa-link">figure 5F–5I</a>). A similar pattern was observed in spleen cells (<a href="#SP1" class="usa-link">online supplemental figure S9F–I</a>), except for CD107a/IFN-γ double-positive CD8+ T cells, which were significantly more abundant in spleens from VSV-GP-treated mice at 7 dpt.</p>
<p>These results demonstrated higher levels of IFN-γ production in CD8+ T cells following VSV-GP-IL12 treatment and confirmed the functional capacity of both CD43<sup>pos</sup>KLRG1<sup>pos</sup> and CD43<sup>neg</sup>KLRG1<sup>pos</sup> CD8+ T subpopulations to produce IFN-γ.</p></section><section id="s3-6"><h3 class="pmc_sec_title">Depletion of CD8+ T cells, but not NK cells, reduces the improved therapeutic efficacy of VSV-GP-IL12 treatment</h3>
<p>Since we found differences in activation and phenotype of both NK cell and CD8+ T cell responses after VSV-GP and VSV-GP-IL12 treatment, we next aimed to dissect the role of both immune cell types in the improved tumor control seen on VSV-GP-IL12. Therefore, we depleted NK or CD8+ T cells or both together. Depletion of NK and CD8+ T cells was confirmed by flow cytometry (<a href="#SP1" class="usa-link">online supplemental figure S12A</a>). Similar to the previous experiments, VSV-GP injection of 80:20 mixed TC-1 tumor-bearing mice resulted in a better tumor control and significantly prolonged survival over the PBS-treated control animals. More importantly, VSV-GP-IL12 significantly improved survival over VSV-GP treatment. Isotype antibodies used as negative control for the depletion did not affect the therapeutic effect of either virus treatment (<a href="#F6" class="usa-link">figure 6A and B</a>). While CD8+ T cell depletion did not influence therapeutic efficacy of VSV-GP, it abrogated the improved survival of VSV-GP-IL12 treated animals to a level seen after VSV-GP treatment (<a href="#F6" class="usa-link">figure 6A and B</a>). Despite the strong activation of NK cells after VSV-GP-IL12 treatment, NK cell depletion did not negatively affect the efficacy of either virus injection (<a href="#F6" class="usa-link">figure 6A and B</a>). Depletion of both NK and CD8+ T cells did not influence the efficacy of the VSV-GP treatment group, but it reduced the survival of VSV-GP-IL12 treated mice to the level found after VSV-GP treatment (<a href="#F6" class="usa-link">figure 6A and B</a>). Of note, three out of eight mice from the group being depleted for both NK and CD8+T cells needed to be terminated after VSV-GP-IL12 injection due to weight loss adhering to the humane endpoints defined in our animal experimentation license (<a href="#SP1" class="usa-link">online supplemental figure S12B</a>). This indicates that in a situation with a high tumor burden and defective innate immune signaling due to a loss of function in the interferon alpha receptor 1, the depletion of both NK and CD8+ T cells can result in a loss of immune control of the virus, potentially leading to systemic toxicity. This toxicity is possibly due to increased levels of replication and subsequent IL-12 cargo expression. Taken together, these results demonstrated that VSV-GP-IL12 improved tumor control and survival of 80:20 mixed TC-1 tumor-bearing mice in a CD8+-dependent manner. Importantly, all of the long-term surviving mice showed detectable E7-specific response displaying again the CD27<sup>neg</sup>CD43<sup>neg</sup>KLRG1<sup>pos</sup> phenotype at 60 days post treatment (<a href="#SP1" class="usa-link">online supplemental figure S12C</a>). Of note, NK depletion did not impact the LLEC phenotype (<a href="#SP1" class="usa-link">online supplemental figure S12C</a>).</p>
<figure class="fig xbox font-sm" id="F6"><h4 class="obj_head">Figure 6. CD8+T cells, and not NK cells, are responsible for the improved efficacy observed on VSV-GP-IL12 treatment. Mixed TC-1:TC-1<em>ifnar1<sup>−/−</sup></em> (80:20) cells were implanted s.c. in the right flank of C57BL/6J mice. CD8+ T cells or NK cells or both together were depleted in VSV-GP and VSV-GP-IL12 treated animals by i.p. injection of either anti-CD8 (100 µg in 100 µL) (aCD8) or/and anti-NK1.1 (250 μg in 100 µL) (aNK) mAbs or their respective isotype controls (100 µg in 100 µL) at day 8, 10, 14, 17 and 21 post tumor implantation. Mice were treated intravenously either with phosphate-buffered saline (control) or 1×10<sup>7</sup> TCID<sub>50</sub> VSV-GP or VSV-GP-IL12 on day 11 post implantation. VSV-GP and VSV-GP-IL12 treatments alone without any antibody treatments are depicted as w/o groups. (<strong>A</strong>) Tumor growth curves and (<strong>B</strong>) survival of the animals are depicted with red numbers indicating long-term survivors within a group (n=8 mice per group). Data were analyzed using log-rank (Mantel-Cox) tests: control versus VSV-GP p=0.0304; control versus VSV-GP-IL12 p=0.0003; VSV-GP versus VSV-GP-IL12 p=0.0009; control versus iso VSV-GP p=0.0113; control versus iso VSV-GP-IL12 p=0.0002; VSV-GP versus iso VSV-GP p=0.7873; VSV-GP-IL12 versus iso VSV-GP-IL12 p=0.3741; control versus aCD8 VSV-GP p=0.0435; control versus aCD8 VSV-GP-IL12 p=0.0011; VSV-GP versus aCD8 VSV-GP p=0.8923; VSV-GP-IL12 versus aCD8 VSV-GP-IL12 p=0.0042; control versus aNK VSV-GP p=0.0849; control versus aNK VSV-GP-IL12 p&lt;0.0001; VSV-GP versus aNK VSV-GP p=0.6872; VSV-GP-IL12 versus aNK VSV-GP-IL12 p=0.3610; control versus aCD8/aNK VSV-GP p=0.0533; control versus aCD8/aNK VSV-GP-IL12 p=0.1121; VSV-GP versus aCD8/aNK VSV-GP p=0.5646; VSV-GP-IL12 versus aCD8/aNK VSV-GP-IL12 p=0.0005. GP, glycoprotein; IL, interleukin; i.p., intraperitoneal; mAbs, monoclonal antibodies; NK, natural killer; s.c., subcutaneous; VSV, vesicular stomatitis virus.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12366581_jitc-13-8-g006.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0382/12366581/a92e61e60aec/jitc-13-8-g006.jpg" loading="lazy" height="537" width="735" alt="Figure 6"></a></p>
<div class="p text-right font-secondary"><a href="figure/F6/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></figure></section><section id="s3-7"><h3 class="pmc_sec_title">VSV-GP-IL12 supports the control of TC-1 tumors in bilateral tumor model in combination with a VSV-GP-based cancer vaccine</h3>
<p>All these results suggested that the tumor control in the mixed TC-1: TC-1<em>ifnar1<sup>−/−</sup></em> model was the result of oncolytic activity as well as antiviral and potentially E7-specific antitumor CD8+ T cell responses. Importantly, long-term survival achieved by VSV-GP-IL12 was associated with the presence of HPV E7-specific antitumor CD8 T-cell responses displaying in particular a CD27<sup>neg</sup>CD43<sup>neg</sup>KLRG1<sup>pos</sup> phenotype. Thus, the IL-12-induced LLEC phenotype may play a role in the context of tumor vaccines, driving a potent tumor-specific CD8+ T cell response for effective tumor control. Therefore, we used VSV-GP encoding E7 as a vaccine component (Vacc), along with either VSV-GP or VSV-GP-IL12, to induce E7-specific CD8+ T cells. To dissect the importance of oncolytic activity, antiviral and E7-specific antitumor CD8+ T cell responses, which might be involved in the virus-permissive 80:20 mixed TC-1 tumor model, we implanted, in addition to the 80:20 mixed TC-1 tumors (right flank), contralateral wild-type TC-1 cells (left flank) that are non-permissive and non-responsive to either virus treatment. In this tumor model, we hypothesized that the control of non-permissive wild-type TC-1 tumors on the contralateral side is primarily related to the quantity and quality of VSV-GPVacc-induced tumor-specific E7 CD8+ T cell responses, with oncolytic and antiviral activities playing a comparatively minor role.</p>
<p>By using this tumor model, the permissive mixed TC-1: TC-1<em>ifnar1<sup>−/−</sup></em> tumors on the right flank showed a similar tumor control after VSV-GPVacc/VSV-GP and VSV-GPVacc/VSV-GP-IL12 treatment (<a href="#F7" class="usa-link">figure 7A</a>). In contrast, the growth of non-permissive contralateral TC-1 tumors was slightly delayed on VSV-GPVacc/VSV-GP compared with control animals, whereas VSV-GPVacc/VSV-GP-IL12 showed a more pronounced effect on the contralateral tumor control, which in turn prolonged the survival of VSV-GPVacc/VSV-GP-IL12 treated mice (<a href="#F7" class="usa-link">figure 7A and B</a>). The difference in the therapeutic outcome between VSV-GPVacc/VSV-GP and VSV-GPVacc/VSV-GP-IL12 was not associated with the level of E7-specific responses as both treatments induced similar frequencies of tumor-specific CD8+T cells (<a href="#F7" class="usa-link">figure 7C</a>). However, a significant difference in the phenotype of E7-specific CD8+ T cells between treatments was found. Whereas E7-specific CD8+ T cells induced by VSV-GPVacc/VSV-GP showed significantly higher frequencies of both CD27<sup>pos</sup> and CD43<sup>pos</sup> cells, VSV-GPVacc/VSV-GP-IL12 treatment resulted in an E7-specific response with significantly higher proportion of KLRG1<sup>pos</sup> CD8+ T cells at 14 days post treatment (<a href="#F7" class="usa-link">figure 7C</a>). This, in turn, resulted in higher frequencies of the CD27<sup>pos</sup>CD43<sup>pos</sup>KLRG1<sup>neg</sup> subset of E7-specific CD8+ T cells in response to VSV-GPVacc/VSV-GP, whereas VSV-GPVacc/VSV-GP-IL12 promoted the generation of E7-specific CD8+ T cells with a CD27<sup>neg</sup>CD43<sup>neg</sup>KLRG1<sup>pos</sup> phenotype (<a href="#F7" class="usa-link">figure 7D</a> and <a href="#SP1" class="usa-link">online supplemental figure S13</a>). Detailed statistical analysis of the different populations comparing Vacc/GP and Vacc/GP-IL12 treatments can be found in <a href="#SP1" class="usa-link">online supplemental table 7</a>. Importantly, all long-term surviving mice showed E7-specific CD8+ T cell response 109 days post treatment (<a href="#SP1" class="usa-link">online supplemental figure S14B, C</a>). As LLEC are also characterized by the expression of CX3CR1,<a href="#R21" class="usa-link" aria-describedby="R21"><sup>21 22</sup></a> we measured the expression of this receptor on E7-specific CD8+ T cells in long-term survivors and found a more pronounced expression of CX3CR1 on specific cells after VSV-GPVacc/VSV-GP-IL12 immunizations compared with VSV-GPVacc/VSV-GP treatment (<a href="#SP1" class="usa-link">online supplemental figure S14C</a>). Moreover, E7 response after VSV-GP was associated with an equal proportion of CD27<sup>pos</sup>CD43<sup>pos</sup>KLRG1<sup>neg</sup> and CD27<sup>neg</sup>CD43<sup>neg</sup>KLRG1<sup>pos</sup> subsets of CD8+ T cells (<a href="#SP1" class="usa-link">online supplemental figure S14D</a>). In contrast, E7-specific CD8+ T cells showed a predominant CD27<sup>neg</sup>CD43<sup>neg</sup>KLRG1<sup>pos</sup> phenotype in mice treated with VSV-GPVacc/VSV-GP-IL12 (<a href="#SP1" class="usa-link">online supplemental figure S14D</a>). CD27<sup>neg</sup>CD43<sup>neg</sup>KLRG1<sup>pos</sup> cells expressed CX3CR1 independent of whether generated on VSV-GPVacc/VSV-GP or VSV-GPVacc/VSV-GP-IL12 treatment (<a href="#SP1" class="usa-link">online supplemental figure S14D</a>).</p>
<figure class="fig xbox font-sm" id="F7"><h4 class="obj_head">Figure 7. VSV-GP-IL12 treatment supports the control of TC-1 tumors in a bilateral tumor model in combination with a VSV-GP-based cancer vaccine. C57Bl/6J mice were inoculated s.c. with mixed TC-1:TC-1<em>ifnar1<sup>−/−</sup></em> (80:20) into the right flank and in parallel TC-1 wild-type cells alone were injected into the left flank. Mice (n=13–15 per group) were treated at 10 days intravenous either with PBS (control), or in combination of E7-encoding VSV-GP-based cancer vaccine (Vacc) with VSV-GP (Vacc/GP) or VSV-GP-IL12 (Vacc/GP-IL12) in a 1:1 ratio with a TCID<sub>50</sub> of 1×10<sup>7</sup> from each component. (<strong>A</strong>) Tumor growth curves of the right and left tumor of PBS-treated, Vacc/GP-treated and Vacc/GP-IL12-treated tumor-bearing mice and (<strong>B</strong>) survival of the animals indicating the median survival are depicted. Pairwise log-rank test was performed. (<strong>C</strong>) Frequencies of E7-specific CD8+ T cells and the expression of surface activation markers (CD27, CD43 and KLRG1) on E7-tetramer positive CD8+ T cells at day 14 post treatments are shown. (<strong>D</strong>) Relative proportions of distinct subpopulations of E7-specific CD8+ T cells based on their expression of CD27, CD43 and KLRG1 from VSV-GP and VSV-GP-IL12 treatment groups. Detailed statistical analysis of the different populations comparing Vacc/GP and Vacc/GP-IL12 treatments can be found in <a href="#SP1" class="usa-link">online supplemental table 7</a>. GP, glycoprotein; IL, interleukin; PBS, phosphate-buffered saline; s.c., subcutaneous; VSV, vesicular stomatitis virus.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12366581_jitc-13-8-g007.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0382/12366581/f7310d95a1c0/jitc-13-8-g007.jpg" loading="lazy" height="516" width="735" alt="Figure 7"></a></p>
<div class="p text-right font-secondary"><a href="figure/F7/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></figure></section></section><section id="s4"><h2 class="pmc_sec_title">Discussion</h2>
<p>In our study, we demonstrated that VSV-GP encoding IL-12 increases the efficacy of oncolytic virotherapy in a subcutaneous TC-1/TC-1<em>ifnar1<sup>−/−</sup></em> mixed tumor model. The improved efficacy by VSV-GP-IL12 treatment was accompanied by the generation of CD8+ T cell responses, which were characterized by a predominant CD27<sup>neg</sup>CD43<sup>neg</sup>KLRG1<sup>pos</sup> phenotype when compared with VSV-GP treatment. As this phenotype correlated with efficacy and was found predominantly also on tumor-specific CD8+ T cells in mice with long-term survival, this CD8+ T subpopulation is likely involved in long-term tumor control.</p>
<p>Several OVs engineered to express IL-12, including herpes simplex virus, adenovirus, measles virus, Maraba virus, Newcastle disease virus, vaccinia virus, Semliki Forest virus, Sindbis virus and also VSV, have been investigated for their potential to enhance antitumor immune responses and have been reviewed in detail recently.<a href="#R41" class="usa-link" aria-describedby="R41"><sup>41 42</sup></a> In a recent study, intratumoral treatment with a recombinant VSV co-expressing both murine IL-12 and granulocyte-macrophage colony-stimulating factor (GM-CSF) (rVSV-mIL-12-GM-CSF) prolongs survival of mice in a subcutaneous B16-F10 murine melanoma model; however, the underlying mechanisms remain to be elucidated.<a href="#R43" class="usa-link" aria-describedby="R43"><sup>43</sup></a> An earlier study also shows significantly improved therapeutic efficacy with intratumoral rVSV-IL-12 in a subcutaneous murine squamous cell carcinoma (SCC VII) model.<a href="#R44" class="usa-link" aria-describedby="R44"><sup>44</sup></a> While these studies with VSV have not extensively investigated underlying mechanisms, the improved therapeutic efficacy of IL-12 delivered by other OVs has been primarily involved in Th1 differentiation, promoted IFN-γ production, increased CD8+ T cell tumor infiltration and increased CD8+ T cell and NK cell activation.<a href="#R39" class="usa-link" aria-describedby="R39"><sup>39 40</sup></a> Our results on IFN-γ production after VSV-GP-IL12 treatments support these observations. Furthermore, the LLEC phenotype, which we found to be stimulated by IL-12 in the context of VSV-GP, provides further insight into mechanisms through which IL-12 supports antitumor immune responses.</p>
<p>VSV-GP represents a potent OV platform and has already been evaluated for its therapeutic potential in preclinical settings.<a href="#R4" class="usa-link" aria-describedby="R4"><sup>4 6 10 25 34</sup></a> Similar to VSV, VSV-GP is highly sensitive to type I IFN-mediated innate immune responses and therefore viral replication is strongly restricted in healthy cells. In contrast, cancer cells often acquire mutations in genes related to intrinsic type I IFN pathways leading to dysregulated IFN responsiveness and making them susceptible to type I IFN-sensitive OV therapies.<a href="#R8" class="usa-link" aria-describedby="R8"><sup>8</sup></a> Numerous tumor cell lines have been demonstrated to have high susceptibility to VSV-GP infection in vitro; however, they may still respond to exogenous IFN-α systemically induced by VSV-GP in vivo.<a href="#R8" class="usa-link" aria-describedby="R8"><sup>8</sup></a> This, in turn, not only reduces VSV-GP infection and subsequent oncolytic activity in vivo but may also limit the production of potential immunomodulatory cargos encoded by the virus. Here, we used a mixed TC-1:TC-1<em>ifnar1<sup>−/−</sup></em> model, allowing effective VSV-GP replication within the tumor. This resulted in a sustained presence of measurable IL-12 levels after VSV-GP-IL12 treatment in the peripheral blood and within the tumor over several days. In addition to allowing the evaluation of immunomodulatory cargos encoded by type I IFN-sensitive OVs like VSV-GP, this mixed model might also better reflect the intratumoral heterogeneity observed in different cancer types.<a href="#R45" class="usa-link" aria-describedby="R45"><sup>45</sup></a> Although the mixed TC-1 model might recapitulate some degree of intratumor heterogeneity of type I IFN responsiveness, it does not fully reflect the native TME. Therefore, further studies will be necessary on other syngeneic tumor models as well as orthotopic models to evaluate the potential of VSV-GP-IL12 in more representative TME. Furthermore, our results underscore the importance of carefully screening and selection of patients for therapies involving VSV-GP or other type I IFN-sensitive OVs, particularly considering the type I IFN responsiveness in tumor cells. This is especially critical in the context of immunomodulatory cargos encoded by such viruses to achieve an optimal therapeutic outcome while minimizing the risk of adverse events. The observed weight loss in certain mice following the simultaneous depletion of both NK cells and CD8+ T cells indicates that the status of both innate and adaptive immune system is a key consideration for the safe use of VSV-GP-IL12.</p>
<p>Permissiveness of tumor cells to VSV-GP infection in the mixed TC-1:TC-1<em>ifnar1<sup>−/−</sup></em> model is likely a key factor contributing to significant oncolytic activity, which is considered an important component for the overall therapeutic efficacy of OVs.<a href="#R6" class="usa-link" aria-describedby="R6"><sup>6 8</sup></a> Previous investigations in a type I IFN receptor-deficient Lewis Lung Carcinoma (LLC) mouse lung cancer model highlighted the predominance of lytic activity for the therapeutic effectiveness following VSV-GP treatment.<a href="#R3" class="usa-link" aria-describedby="R3"><sup>3</sup></a> Consistent with our present study, CD8+ T cell depletion did not adversely impact the efficacy of VSV-GP treatment in type I IFN receptor-deficient LLC model<a href="#R3" class="usa-link" aria-describedby="R3"><sup>3</sup></a> suggesting a limited contribution of the antiviral/antitumor adaptive immunity by VSV-GP treatment. Similarly, the relatively strong antiviral CD8+ T cell activation and sporadically induced antitumor E7-specific CD8+ T cells in response to VSV-GP therapy do not significantly contribute to therapeutic efficacy. However, CD8+ T cell depletion clearly reduced the efficacy of VSV-GP-IL12 to a level comparable to that observed after VSV-GP treatment. Notably, the frequencies of both antiviral and E7-specific antitumor CD8+ T cells responses did not significantly differ between VSV-GP and VSV-GP-IL12 treatment. This suggested not the magnitude of CD8+ T cell response, but phenotypical and functional differences in CD8+ T cells might be critically involved in the enhanced therapeutic outcome observed after VSV-GP-IL12 treatment.</p>
<p>Despite its potential for systemic toxicity, IL-12 represents a potent immune modulatory molecule in the realm of cancer immunotherapies exerting antitumor activity in a wide range of preclinical tumor models. IL-12 supports antitumor immunity by boosting CD8+ T cell and NK cell responses particularly through the induction of IFN-γ production.<a href="#R46" class="usa-link" aria-describedby="R46"><sup>46</sup></a> Efforts are underway to develop strategies for safe IL-12 delivery, with a primary focus on targeted delivery specifically to the tumor site aiming to enhance therapeutic outcomes, widen the therapeutic window, and minimize adverse effects.<a href="#R47" class="usa-link" aria-describedby="R47">47</a>,<a href="#R50" class="usa-link" aria-describedby="R50">50</a> In our study, VSV-GP-IL12 treatment was associated with CD8+ T cell activation characterized by a predominant presence of cells exhibiting a CD27<sup>neg</sup>CD43<sup>neg</sup>KLRG1<sup>pos</sup> phenotype compared with VSV-GP. Specific CD8+ T cells with a similar phenotype have been described in response to LCMV infection in mice and termed as LLEC<a href="#R21" class="usa-link" aria-describedby="R21"><sup>21 22</sup></a> or terminally differentiated effector memory cells (terminal-TEM).<a href="#R23" class="usa-link" aria-describedby="R23"><sup>23</sup></a> According to the phenotype described for both LLEC and terminal-TEM, CD8+ T cells induced after VSV-GP-IL12 treatment were mainly CD44<sup>pos</sup>CD62L<sup>neg</sup> TE/TEM cells and expressed the fractalkine-receptor CX3CR1 on their surface.<a href="#R21" class="usa-link" aria-describedby="R21">21</a>,<a href="#R23" class="usa-link" aria-describedby="R23">23</a> CX3CR1 is thought to be present on antigen-experienced CD8+ T cells and expression is accompanied by cytotoxic effector functions of CD8+ T cells at both effector and memory phase after adenovirus, LCMV or <em>Listeria monocytogenes</em> infection.<a href="#R51" class="usa-link" aria-describedby="R51"><sup>51</sup></a> Whereas these phenotypes have been described in the context of T cell-mediated pathogen control, little is known about a potential role of these cells in antitumor immunity. During the induction of a CD8+ T cell response, the expansion of specific CD8+ T cells results in the formation of SLEC and the development of memory cells, including both TEM and TCM populations. Whereas SLECs display significant cytotoxic capacity, TEM and TCM play essential roles in providing long-lasting immunity and facilitating recall responses.<a href="#R52" class="usa-link" aria-describedby="R52"><sup>52</sup></a> The activation and memory development of CD8+ T cells is accompanied with the expression of surface and intracellular markers defining heterogeneous populations at different activation and differentiation stages. Both LLEC and terminal-TEM have been shown to differ from classical TEM and TCM cells as well as from SLECs, whereby they represent a long-lived effector-like cell type in the memory population possessing characteristic of memory T cells with potent cytotoxic capacity.<a href="#R21" class="usa-link" aria-describedby="R21"><sup>21 23</sup></a> Our study demonstrates that CD27<sup>neg</sup>CD43<sup>neg</sup>KLRG1<sup>pos</sup> LLECs are as potent as other activated CD8+ T cell populations (CD43<sup>pos</sup>KLRG1<sup>neg</sup> and CD43<sup>pos</sup>KLRG1<sup>pos</sup>) in IFN-γ production and degranulation following peptide stimulation. Given their long-lived nature and potent cytotoxic capacity, LLECs might be beneficial for long-term tumor control. Notably, not all mice treated with VSV-GP-IL12 generate an E7-specific antitumor CD8+ T cell response. However, all long-term survivors investigated exhibit E7-specific CD8+ T cells along with an accumulation of LLECs, suggesting a critical role for these cells in sustained tumor control. Interestingly, early induction of E7-specific CD8+T cells does not always correlate with long-term survival, indicating that additional factors within the TME likely influence therapeutic success.</p>
<p>The factors governing the development of LLEC or terminal-TEM are not fully understood, but KLRG1+ effector CD8+ T cells, present as early as 12 days post infection, appear to be the major source of LLECs following LCMV infection.<a href="#R21" class="usa-link" aria-describedby="R21"><sup>21</sup></a> KLRG1 is often referred to as a marker for SLEC.<a href="#R53" class="usa-link" aria-describedby="R53"><sup>53</sup></a> Inflammatory signals like IL-12 during the priming have been shown to regulate the development of KLRG1+IL-7R<sub>low</sub> SLEC.<a href="#R54" class="usa-link" aria-describedby="R54"><sup>54</sup></a> This suggests that the sustained IL-12 production in the mixed TC-1 model after VSV-GP-IL12 is likely involved in the increase of KLRG1+CD8+ T cell frequencies, thereby giving the source of LLECs or terminal-TEM. Furthermore, VSV-GP-IL12 treatment induced a rapid downregulation of CD27 on activated CD8+ T cells already seen after 7 days post treatment. CD27 on CD8+T cells has been shown to be downregulated after repeated antigen stimulation.<a href="#R32" class="usa-link" aria-describedby="R32"><sup>32</sup></a> In line with this observation, antigen boost increased the frequency of CD27<sup>low</sup>CD43<sup>low</sup>KLRG1<sup>high</sup> CD8+ T cells.<a href="#R22" class="usa-link" aria-describedby="R22"><sup>22</sup></a> The lack of CD27 on murine CD8+ T cells has been proposed to identify CD8+ memory T-cell population with expression of cytotoxic molecules like granzyme B and perforin.<a href="#R32" class="usa-link" aria-describedby="R32"><sup>32</sup></a> Therefore, we propose that sustained IL-12 production in mixed TC-1:TC-1<em>ifnar1<sup>−/−</sup></em> model following VSV-GP-IL12 treatment induces a molecular reprogramming of activated CD8+ T cells and drives the generation of long-lived CD8+ T likely LLECs or terminal-TEM cells that are highly effective in controlling tumor growth. We propose that the lack of CD43 expression on KLRG1<sup>pos</sup>CD127<sup>neg</sup> CD8+ T cells, traditionally classified as SLECs, might help distinguish developing LLECs within the SLEC population in early time points. How IL-12 promotes the development of long-lived CD8+ T cells is not clear and needs to be further investigated. Notably, VSV-GP treatment of TC-1/TC-1<em>ifnar1<sup>−/−</sup></em> tumors mixed at a 20:80 ratio also leads to an increase in CD27<sup>neg</sup>CD43<sup>pos</sup>KLRG1<sup>pos</sup> population, along with a slight increase in LLECs, suggesting that IL-12 may not be the only factor driving this effect. While our findings strongly support a role for IL-12 encoded by VSV-GP in promoting LLEC phenotype, further investigations are needed to determine the extent of IL-12’s involvement and to identify additional contributing factors. Understanding the underlying mechanisms by which IL-12 influences the development of LLEC phenotype of CD8+ T cells holds promise for the development of safer therapeutic strategies that harness robust antitumor immune responses.</p>
<p>Taken together, we demonstrated for the first time that IL-12 production by VSV-GP treatment in a mouse tumor model is therapeutically effective and preferentially induced a CD8+ T cell response characterized by CD27<sup>neg</sup>CD43<sup>neg</sup>KLRG1<sup>pos</sup> long-lived, likely LLEC or terminal-TEM cell phenotype. This study strongly supports the hypothesis that this CD8+ T cell population is crucial for tumor control.</p></section><section id="s5"><h2 class="pmc_sec_title">Supplementary material</h2>
<section class="sm xbox font-sm" id="SP1"><div class="caption p"><span>online supplemental file 1</span></div>
<div class="media p" id="d67e1708">
<div class="caption">
<a href="/articles/instance/12366581/bin/jitc-13-8-s001.docx" data-ga-action="click_feat_suppl" class="usa-link">jitc-13-8-s001.docx</a><sup> (35.3MB, docx) </sup>
</div>
<div class="object-id font-xs text-base-dark">DOI: 10.1136/jitc-2024-010675</div>
</div></section></section><section id="ack1" class="ack"><h2 class="pmc_sec_title">Acknowledgements</h2>
<p>We thank Nita Venkatesh, and Jaqueline Schörgenhuber for excellent technical assistance.</p></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2>
<div class="fn-group p font-secondary-light font-sm">
<div class="fn p" id="fn4_pmc"><p><strong>Funding:</strong> G.W. is supported by the Christian Doppler Research Association.</p></div>
<div class="fn p" id="fn5"><p><strong>Provenance and peer review:</strong> Not commissioned; externally peer reviewed.</p></div>
<div class="fn p" id="fn6"><p><strong>Patient consent for publication:</strong> Not applicable.</p></div>
<div class="fn p" id="fn7"><p><strong>Ethics approval:</strong> Not applicable.</p></div>
<div class="fn p" id="fn8"><p><strong>Data availability free text:</strong> All raw data, and materials are available from the corresponding author upon request. All data supporting the findings of this study are available in the paper and in the supplemental material.</p></div>
</div></section><section id="sec30"><h2 class="pmc_sec_title">Data availability statement</h2>
<p>All data relevant to the study are included in the article or uploaded as supplementary information.</p></section><section id="ref-list1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="ref-list1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="R1">
<span class="label">1.</span><cite>Chesney JA, Ribas A, Long GV, et al.  Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma. JCO. 2023;41:528–40. doi: 10.1200/JCO.22.00343.</cite> [<a href="https://doi.org/10.1200/JCO.22.00343" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9870217/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35998300/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JCO&amp;title=Randomized,%20Double-Blind,%20Placebo-Controlled,%20Global%20Phase%20III%20Trial%20of%20Talimogene%20Laherparepvec%20Combined%20With%20Pembrolizumab%20for%20Advanced%20Melanoma&amp;author=JA%20Chesney&amp;author=A%20Ribas&amp;author=GV%20Long&amp;volume=41&amp;publication_year=2023&amp;pages=528-40&amp;pmid=35998300&amp;doi=10.1200/JCO.22.00343&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R2">
<span class="label">2.</span><cite>Porosnicu M, Quinson A-M, Crossley K, et al.  Phase I study of VSV-GP (BI 1831169) as monotherapy or combined with ezabenlimab in advanced and refractory solid tumors. Future Oncol. 2022;18:2627–38. doi: 10.2217/fon-2022-0439.</cite> [<a href="https://doi.org/10.2217/fon-2022-0439" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35699077/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Future%20Oncol&amp;title=Phase%20I%20study%20of%20VSV-GP%20(BI%201831169)%20as%20monotherapy%20or%20combined%20with%20ezabenlimab%20in%20advanced%20and%20refractory%20solid%20tumors&amp;author=M%20Porosnicu&amp;author=A-M%20Quinson&amp;author=K%20Crossley&amp;volume=18&amp;publication_year=2022&amp;pages=2627-38&amp;pmid=35699077&amp;doi=10.2217/fon-2022-0439&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R3">
<span class="label">3.</span><cite>Schreiber L-M, Urbiola C, Das K, et al.  The lytic activity of VSV-GP treatment dominates the therapeutic effects in a syngeneic model of lung cancer. Br J Cancer. 2019;121:647–58. doi: 10.1038/s41416-019-0574-7.</cite> [<a href="https://doi.org/10.1038/s41416-019-0574-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6889376/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31530903/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Br%20J%20Cancer&amp;title=The%20lytic%20activity%20of%20VSV-GP%20treatment%20dominates%20the%20therapeutic%20effects%20in%20a%20syngeneic%20model%20of%20lung%20cancer&amp;author=L-M%20Schreiber&amp;author=C%20Urbiola&amp;author=K%20Das&amp;volume=121&amp;publication_year=2019&amp;pages=647-58&amp;pmid=31530903&amp;doi=10.1038/s41416-019-0574-7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R4">
<span class="label">4.</span><cite>Das K, Belnoue E, Rossi M, et al.  A modular self-adjuvanting cancer vaccine combined with an oncolytic vaccine induces potent antitumor immunity. Nat Commun. 2021;12:5195.  doi: 10.1038/s41467-021-25506-6.</cite> [<a href="https://doi.org/10.1038/s41467-021-25506-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8408233/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34465781/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Commun&amp;title=A%20modular%20self-adjuvanting%20cancer%20vaccine%20combined%20with%20an%20oncolytic%20vaccine%20induces%20potent%20antitumor%20immunity&amp;author=K%20Das&amp;author=E%20Belnoue&amp;author=M%20Rossi&amp;volume=12&amp;publication_year=2021&amp;pages=5195&amp;pmid=34465781&amp;doi=10.1038/s41467-021-25506-6&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R5">
<span class="label">5.</span><cite>Muik A, Stubbert LJ, Jahedi RZ, et al.  Re-engineering vesicular stomatitis virus to abrogate neurotoxicity, circumvent humoral immunity, and enhance oncolytic potency. 
Cancer Res
. 2014;74:3567–78. doi: 10.1158/0008-5472.CAN-13-3306.</cite> [<a href="https://doi.org/10.1158/0008-5472.CAN-13-3306" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24812275/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Res&amp;title=Re-engineering%20vesicular%20stomatitis%20virus%20to%20abrogate%20neurotoxicity,%20circumvent%20humoral%20immunity,%20and%20enhance%20oncolytic%20potency&amp;author=A%20Muik&amp;author=LJ%20Stubbert&amp;author=RZ%20Jahedi&amp;volume=74&amp;publication_year=2014&amp;pages=3567-78&amp;pmid=24812275&amp;doi=10.1158/0008-5472.CAN-13-3306&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R6">
<span class="label">6.</span><cite>Urbiola C, Santer FR, Petersson M, et al.  Oncolytic activity of the rhabdovirus VSV-GP against prostate cancer. Int J Cancer. 2018;143:1786–96. doi: 10.1002/ijc.31556.</cite> [<a href="https://doi.org/10.1002/ijc.31556" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6712949/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29696636/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int%20J%20Cancer&amp;title=Oncolytic%20activity%20of%20the%20rhabdovirus%20VSV-GP%20against%20prostate%20cancer&amp;author=C%20Urbiola&amp;author=FR%20Santer&amp;author=M%20Petersson&amp;volume=143&amp;publication_year=2018&amp;pages=1786-96&amp;pmid=29696636&amp;doi=10.1002/ijc.31556&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R7">
<span class="label">7.</span><cite>Stojdl DF, Lichty B, Knowles S, et al.  Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med. 2000;6:821–5. doi: 10.1038/77558.</cite> [<a href="https://doi.org/10.1038/77558" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/10888934/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Med&amp;title=Exploiting%20tumor-specific%20defects%20in%20the%20interferon%20pathway%20with%20a%20previously%20unknown%20oncolytic%20virus&amp;author=DF%20Stojdl&amp;author=B%20Lichty&amp;author=S%20Knowles&amp;volume=6&amp;publication_year=2000&amp;pages=821-5&amp;pmid=10888934&amp;doi=10.1038/77558&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R8">
<span class="label">8.</span><cite>Dold C, Rodriguez Urbiola C, Wollmann G, et al.  Application of interferon modulators to overcome partial resistance of human ovarian cancers to VSV-GP oncolytic viral therapy. Mol Ther Oncolytics. 2016;3:16021. doi: 10.1038/mto.2016.21.</cite> [<a href="https://doi.org/10.1038/mto.2016.21" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5040171/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27738655/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Mol%20Ther%20Oncolytics&amp;title=Application%20of%20interferon%20modulators%20to%20overcome%20partial%20resistance%20of%20human%20ovarian%20cancers%20to%20VSV-GP%20oncolytic%20viral%20therapy&amp;author=C%20Dold&amp;author=C%20Rodriguez%20Urbiola&amp;author=G%20Wollmann&amp;volume=3&amp;publication_year=2016&amp;pages=16021&amp;pmid=27738655&amp;doi=10.1038/mto.2016.21&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R9">
<span class="label">9.</span><cite>Gujar SA, Pan DA, Marcato P, et al.  Oncolytic virus-initiated protective immunity against prostate cancer. Mol Ther. 2011;19:797–804. doi: 10.1038/mt.2010.297.</cite> [<a href="https://doi.org/10.1038/mt.2010.297" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3070098/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21245852/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Mol%20Ther&amp;title=Oncolytic%20virus-initiated%20protective%20immunity%20against%20prostate%20cancer&amp;author=SA%20Gujar&amp;author=DA%20Pan&amp;author=P%20Marcato&amp;volume=19&amp;publication_year=2011&amp;pages=797-804&amp;pmid=21245852&amp;doi=10.1038/mt.2010.297&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R10">
<span class="label">10.</span><cite>Kimpel J, Urbiola C, Koske I, et al.  The Oncolytic Virus VSV-GP Is Effective against Malignant Melanoma. Viruses. 2018;10:108.  doi: 10.3390/v10030108.</cite> [<a href="https://doi.org/10.3390/v10030108" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5869501/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29498639/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Viruses&amp;title=The%20Oncolytic%20Virus%20VSV-GP%20Is%20Effective%20against%20Malignant%20Melanoma&amp;author=J%20Kimpel&amp;author=C%20Urbiola&amp;author=I%20Koske&amp;volume=10&amp;publication_year=2018&amp;pages=108&amp;pmid=29498639&amp;doi=10.3390/v10030108&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R11">
<span class="label">11.</span><cite>Lichty BD, Breitbach CJ, Stojdl DF, et al.  Going viral with cancer immunotherapy. Nat Rev Cancer. 2014;14:559–67. doi: 10.1038/nrc3770.</cite> [<a href="https://doi.org/10.1038/nrc3770" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24990523/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Rev%20Cancer&amp;title=Going%20viral%20with%20cancer%20immunotherapy&amp;author=BD%20Lichty&amp;author=CJ%20Breitbach&amp;author=DF%20Stojdl&amp;volume=14&amp;publication_year=2014&amp;pages=559-67&amp;pmid=24990523&amp;doi=10.1038/nrc3770&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R12">
<span class="label">12.</span><cite>Grohmann U, Belladonna ML, Vacca C, et al.  Positive regulatory role of IL-12 in macrophages and modulation by IFN-gamma. J Immunol. 2001;167:221–7. doi: 10.4049/jimmunol.167.1.221.</cite> [<a href="https://doi.org/10.4049/jimmunol.167.1.221" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11418652/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Immunol&amp;title=Positive%20regulatory%20role%20of%20IL-12%20in%20macrophages%20and%20modulation%20by%20IFN-gamma&amp;author=U%20Grohmann&amp;author=ML%20Belladonna&amp;author=C%20Vacca&amp;volume=167&amp;publication_year=2001&amp;pages=221-7&amp;pmid=11418652&amp;doi=10.4049/jimmunol.167.1.221&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R13">
<span class="label">13.</span><cite>Ma X, Chow JM, Gri G, et al.  The interleukin 12 p40 gene promoter is primed by interferon gamma in monocytic cells. J Exp Med. 1996;183:147–57. doi: 10.1084/jem.183.1.147.</cite> [<a href="https://doi.org/10.1084/jem.183.1.147" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2192398/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/8551218/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Exp%20Med&amp;title=The%20interleukin%2012%20p40%20gene%20promoter%20is%20primed%20by%20interferon%20gamma%20in%20monocytic%20cells&amp;author=X%20Ma&amp;author=JM%20Chow&amp;author=G%20Gri&amp;volume=183&amp;publication_year=1996&amp;pages=147-57&amp;pmid=8551218&amp;doi=10.1084/jem.183.1.147&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R14">
<span class="label">14.</span><cite>Hewitt SL, Bailey D, Zielinski J, et al.  Intratumoral IL12 mRNA Therapy Promotes TH1 Transformation of the Tumor Microenvironment. Clin Cancer Res. 2020;26:6284–98. doi: 10.1158/1078-0432.CCR-20-0472.</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-20-0472" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32817076/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Cancer%20Res&amp;title=Intratumoral%20IL12%20mRNA%20Therapy%20Promotes%20TH1%20Transformation%20of%20the%20Tumor%20Microenvironment&amp;author=SL%20Hewitt&amp;author=D%20Bailey&amp;author=J%20Zielinski&amp;volume=26&amp;publication_year=2020&amp;pages=6284-98&amp;pmid=32817076&amp;doi=10.1158/1078-0432.CCR-20-0472&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R15">
<span class="label">15.</span><cite>Shankaran V, Ikeda H, Bruce AT, et al.  IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature New Biol. 2001;410:1107–11. doi: 10.1038/35074122.</cite> [<a href="https://doi.org/10.1038/35074122" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11323675/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20New%20Biol&amp;title=IFNgamma%20and%20lymphocytes%20prevent%20primary%20tumour%20development%20and%20shape%20tumour%20immunogenicity&amp;author=V%20Shankaran&amp;author=H%20Ikeda&amp;author=AT%20Bruce&amp;volume=410&amp;publication_year=2001&amp;pages=1107-11&amp;pmid=11323675&amp;doi=10.1038/35074122&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R16">
<span class="label">16.</span><cite>Cavallo F, Signorelli P, Giovarelli M, et al.  Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12. J Natl Cancer Inst. 1997;89:1049–58. doi: 10.1093/jnci/89.14.1049.</cite> [<a href="https://doi.org/10.1093/jnci/89.14.1049" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/9230887/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Natl%20Cancer%20Inst&amp;title=Antitumor%20efficacy%20of%20adenocarcinoma%20cells%20engineered%20to%20produce%20interleukin%2012%20(IL-12)%20or%20other%20cytokines%20compared%20with%20exogenous%20IL-12&amp;author=F%20Cavallo&amp;author=P%20Signorelli&amp;author=M%20Giovarelli&amp;volume=89&amp;publication_year=1997&amp;pages=1049-58&amp;pmid=9230887&amp;doi=10.1093/jnci/89.14.1049&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R17">
<span class="label">17.</span><cite>Eisenring M, vom Berg J, Kristiansen G, et al.  IL-12 initiates tumor rejection via lymphoid tissue-inducer cells bearing the natural cytotoxicity receptor NKp46. Nat Immunol. 2010;11:1030–8. doi: 10.1038/ni.1947.</cite> [<a href="https://doi.org/10.1038/ni.1947" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20935648/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Immunol&amp;title=IL-12%20initiates%20tumor%20rejection%20via%20lymphoid%20tissue-inducer%20cells%20bearing%20the%20natural%20cytotoxicity%20receptor%20NKp46&amp;author=M%20Eisenring&amp;author=J%20vom%20Berg&amp;author=G%20Kristiansen&amp;volume=11&amp;publication_year=2010&amp;pages=1030-8&amp;pmid=20935648&amp;doi=10.1038/ni.1947&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R18">
<span class="label">18.</span><cite>Motzer RJ, Rakhit A, Schwartz LH, et al.  Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. Clin Cancer Res. 1998;4:1183–91.</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/9607576/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Cancer%20Res&amp;title=Phase%20I%20trial%20of%20subcutaneous%20recombinant%20human%20interleukin-12%20in%20patients%20with%20advanced%20renal%20cell%20carcinoma&amp;author=RJ%20Motzer&amp;author=A%20Rakhit&amp;author=LH%20Schwartz&amp;volume=4&amp;publication_year=1998&amp;pages=1183-91&amp;pmid=9607576&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R19">
<span class="label">19.</span><cite>Wang P, Li X, Wang J, et al.  Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent. Nat Commun. 2017;8:1395. doi: 10.1038/s41467-017-01385-8.</cite> [<a href="https://doi.org/10.1038/s41467-017-01385-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5680234/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29123084/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Commun&amp;title=Re-designing%20Interleukin-12%20to%20enhance%20its%20safety%20and%20potential%20as%20an%20anti-tumor%20immunotherapeutic%20agent&amp;author=P%20Wang&amp;author=X%20Li&amp;author=J%20Wang&amp;volume=8&amp;publication_year=2017&amp;pages=1395&amp;pmid=29123084&amp;doi=10.1038/s41467-017-01385-8&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R20">
<span class="label">20.</span><cite>Battula S, Papastoitsis G, Kaufman HL, et al.  Intratumoral aluminum hydroxide–anchored IL-12 drives potent antitumor activity by remodeling the tumor microenvironment. JCI Insight. 2023;8:e168224.  doi: 10.1172/jci.insight.168224.</cite> [<a href="https://doi.org/10.1172/jci.insight.168224" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10795832/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38063196/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JCI%20Insight&amp;title=Intratumoral%20aluminum%20hydroxide%E2%80%93anchored%20IL-12%20drives%20potent%20antitumor%20activity%20by%20remodeling%20the%20tumor%20microenvironment&amp;author=S%20Battula&amp;author=G%20Papastoitsis&amp;author=HL%20Kaufman&amp;volume=8&amp;publication_year=2023&amp;pages=e168224&amp;pmid=38063196&amp;doi=10.1172/jci.insight.168224&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R21">
<span class="label">21.</span><cite>Renkema KR, Huggins MA, Borges da Silva H, et al.  KLRG1+ Memory CD8 T Cells Combine Properties of Short-Lived Effectors and Long-Lived Memory. J Immunol. 2020;205:1059–69. doi: 10.4049/jimmunol.1901512.</cite> [<a href="https://doi.org/10.4049/jimmunol.1901512" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7415731/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32611727/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Immunol&amp;title=KLRG1+%20Memory%20CD8%20T%20Cells%20Combine%20Properties%20of%20Short-Lived%20Effectors%20and%20Long-Lived%20Memory&amp;author=KR%20Renkema&amp;author=MA%20Huggins&amp;author=H%20Borges%20da%20Silva&amp;volume=205&amp;publication_year=2020&amp;pages=1059-69&amp;pmid=32611727&amp;doi=10.4049/jimmunol.1901512&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R22">
<span class="label">22.</span><cite>Olson JA, McDonald-Hyman C, Jameson SC, et al.  T cells in the memory population mediate potent protective immunity. Immunity. 2013;38:1250–60. doi: 10.1016/j.immuni.2013.05.009.</cite> [<a href="https://doi.org/10.1016/j.immuni.2013.05.009" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3703254/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23746652/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Immunity&amp;title=T%20cells%20in%20the%20memory%20population%20mediate%20potent%20protective%20immunity&amp;author=JA%20Olson&amp;author=C%20McDonald-Hyman&amp;author=SC%20Jameson&amp;volume=38&amp;publication_year=2013&amp;pages=1250-60&amp;pmid=23746652&amp;doi=10.1016/j.immuni.2013.05.009&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R23">
<span class="label">23.</span><cite>Milner JJ, Nguyen H, Omilusik K, et al.  Delineation of a molecularly distinct terminally differentiated memory CD8 T cell population. Proc Natl Acad Sci U S A. 2020;117:25667–78. doi: 10.1073/pnas.2008571117.</cite> [<a href="https://doi.org/10.1073/pnas.2008571117" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7568335/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32978300/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Proc%20Natl%20Acad%20Sci%20U%20S%20A&amp;title=Delineation%20of%20a%20molecularly%20distinct%20terminally%20differentiated%20memory%20CD8%20T%20cell%20population&amp;author=JJ%20Milner&amp;author=H%20Nguyen&amp;author=K%20Omilusik&amp;volume=117&amp;publication_year=2020&amp;pages=25667-78&amp;pmid=32978300&amp;doi=10.1073/pnas.2008571117&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R24">
<span class="label">24.</span><cite>Volland A, Lohmüller M, Heilmann E, et al.  Heparan sulfate proteoglycans serve as alternative receptors for low affinity LCMV variants. PLoS Pathog. 2021;17:e1009996.  doi: 10.1371/journal.ppat.1009996.</cite> [<a href="https://doi.org/10.1371/journal.ppat.1009996" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8547738/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34648606/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=PLoS%20Pathog&amp;title=Heparan%20sulfate%20proteoglycans%20serve%20as%20alternative%20receptors%20for%20low%20affinity%20LCMV%20variants&amp;author=A%20Volland&amp;author=M%20Lohm%C3%BCller&amp;author=E%20Heilmann&amp;volume=17&amp;publication_year=2021&amp;pages=e1009996&amp;pmid=34648606&amp;doi=10.1371/journal.ppat.1009996&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R25">
<span class="label">25.</span><cite>Tober R, Banki Z, Egerer L, et al.  VSV-GP: a potent viral vaccine vector that boosts the immune response upon repeated applications. J Virol. 2014;88:4897–907. doi: 10.1128/JVI.03276-13.</cite> [<a href="https://doi.org/10.1128/JVI.03276-13" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3993835/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24554655/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Virol&amp;title=VSV-GP:%20a%20potent%20viral%20vaccine%20vector%20that%20boosts%20the%20immune%20response%20upon%20repeated%20applications&amp;author=R%20Tober&amp;author=Z%20Banki&amp;author=L%20Egerer&amp;volume=88&amp;publication_year=2014&amp;pages=4897-907&amp;pmid=24554655&amp;doi=10.1128/JVI.03276-13&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R26">
<span class="label">26.</span><cite>Witko SE, Kotash CS, Nowak RM, et al.  An efficient helper-virus-free method for rescue of recombinant paramyxoviruses and rhadoviruses from a cell line suitable for vaccine development. J Virol Methods. 2006;135:91–101. doi: 10.1016/j.jviromet.2006.02.006.</cite> [<a href="https://doi.org/10.1016/j.jviromet.2006.02.006" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16569439/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Virol%20Methods&amp;title=An%20efficient%20helper-virus-free%20method%20for%20rescue%20of%20recombinant%20paramyxoviruses%20and%20rhadoviruses%20from%20a%20cell%20line%20suitable%20for%20vaccine%20development&amp;author=SE%20Witko&amp;author=CS%20Kotash&amp;author=RM%20Nowak&amp;volume=135&amp;publication_year=2006&amp;pages=91-101&amp;pmid=16569439&amp;doi=10.1016/j.jviromet.2006.02.006&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R27">
<span class="label">27.</span><cite>Kärber G. Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Archiv f experiment Pathol u Pharmakol. 1931;162:480–3. doi: 10.1007/BF01863914.</cite> [<a href="https://doi.org/10.1007/BF01863914" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Archiv%20f%20experiment%20Pathol%20u%20Pharmakol&amp;title=Beitrag%20zur%20kollektiven%20Behandlung%20pharmakologischer%20Reihenversuche&amp;author=G%20K%C3%A4rber&amp;volume=162&amp;publication_year=1931&amp;pages=480-3&amp;doi=10.1007/BF01863914&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R28">
<span class="label">28.</span><cite>Noser JA, Mael AA, Sakuma R, et al.  The RAS/Raf1/MEK/ERK signaling pathway facilitates VSV-mediated oncolysis: implication for the defective interferon response in cancer cells. Mol Ther. 2007;15:1531–6. doi: 10.1038/sj.mt.6300193.</cite> [<a href="https://doi.org/10.1038/sj.mt.6300193" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17505473/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Mol%20Ther&amp;title=The%20RAS/Raf1/MEK/ERK%20signaling%20pathway%20facilitates%20VSV-mediated%20oncolysis:%20implication%20for%20the%20defective%20interferon%20response%20in%20cancer%20cells&amp;author=JA%20Noser&amp;author=AA%20Mael&amp;author=R%20Sakuma&amp;volume=15&amp;publication_year=2007&amp;pages=1531-6&amp;pmid=17505473&amp;doi=10.1038/sj.mt.6300193&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R29">
<span class="label">29.</span><cite>Le Boeuf F, Niknejad N, Wang J, et al.  Sensitivity of cervical carcinoma cells to vesicular stomatitis virus-induced oncolysis: potential role of human papilloma virus infection. Int J Cancer. 2012;131:E204–15. doi: 10.1002/ijc.27404.</cite> [<a href="https://doi.org/10.1002/ijc.27404" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22173567/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int%20J%20Cancer&amp;title=Sensitivity%20of%20cervical%20carcinoma%20cells%20to%20vesicular%20stomatitis%20virus-induced%20oncolysis:%20potential%20role%20of%20human%20papilloma%20virus%20infection&amp;author=F%20Le%20Boeuf&amp;author=N%20Niknejad&amp;author=J%20Wang&amp;volume=131&amp;publication_year=2012&amp;pages=E204-15&amp;pmid=22173567&amp;doi=10.1002/ijc.27404&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R30">
<span class="label">30.</span><cite>Li S, Labrecque S, Gauzzi MC, et al.  The human papilloma virus (HPV)-18 E6 oncoprotein physically associates with Tyk2 and impairs Jak-STAT activation by interferon-alpha. Oncogene. 1999;18:5727–37. doi: 10.1038/sj.onc.1202960.</cite> [<a href="https://doi.org/10.1038/sj.onc.1202960" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/10523853/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncogene&amp;title=The%20human%20papilloma%20virus%20(HPV)-18%20E6%20oncoprotein%20physically%20associates%20with%20Tyk2%20and%20impairs%20Jak-STAT%20activation%20by%20interferon-alpha&amp;author=S%20Li&amp;author=S%20Labrecque&amp;author=MC%20Gauzzi&amp;volume=18&amp;publication_year=1999&amp;pages=5727-37&amp;pmid=10523853&amp;doi=10.1038/sj.onc.1202960&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R31">
<span class="label">31.</span><cite>Herndler-Brandstetter D, Ishigame H, Shinnakasu R, et al.  KLRG1+ Effector CD8+ T Cells Lose KLRG1, Differentiate into All Memory T Cell Lineages, and Convey Enhanced Protective Immunity. Immunity. 2018;48:716–29. doi: 10.1016/j.immuni.2018.03.015.</cite> [<a href="https://doi.org/10.1016/j.immuni.2018.03.015" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6465538/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29625895/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Immunity&amp;title=KLRG1+%20Effector%20CD8+%20T%20Cells%20Lose%20KLRG1,%20Differentiate%20into%20All%20Memory%20T%20Cell%20Lineages,%20and%20Convey%20Enhanced%20Protective%20Immunity&amp;author=D%20Herndler-Brandstetter&amp;author=H%20Ishigame&amp;author=R%20Shinnakasu&amp;volume=48&amp;publication_year=2018&amp;pages=716-29&amp;pmid=29625895&amp;doi=10.1016/j.immuni.2018.03.015&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R32">
<span class="label">32.</span><cite>Baars PA, Sierro S, Arens R, et al.  Properties of murine (CD8+)CD27- T cells. Eur J Immunol. 2005;35:3131–41. doi: 10.1002/eji.200425770.</cite> [<a href="https://doi.org/10.1002/eji.200425770" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16220536/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Immunol&amp;title=Properties%20of%20murine%20(CD8+)CD27-%20T%20cells&amp;author=PA%20Baars&amp;author=S%20Sierro&amp;author=R%20Arens&amp;volume=35&amp;publication_year=2005&amp;pages=3131-41&amp;pmid=16220536&amp;doi=10.1002/eji.200425770&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R33">
<span class="label">33.</span><cite>Harrington LE, Galvan M, Baum LG, et al.  Differentiating between memory and effector CD8 T cells by altered expression of cell surface O-glycans. J Exp Med. 2000;191:1241–6. doi: 10.1084/jem.191.7.1241.</cite> [<a href="https://doi.org/10.1084/jem.191.7.1241" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2193165/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/10748241/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Exp%20Med&amp;title=Differentiating%20between%20memory%20and%20effector%20CD8%20T%20cells%20by%20altered%20expression%20of%20cell%20surface%20O-glycans&amp;author=LE%20Harrington&amp;author=M%20Galvan&amp;author=LG%20Baum&amp;volume=191&amp;publication_year=2000&amp;pages=1241-6&amp;pmid=10748241&amp;doi=10.1084/jem.191.7.1241&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R34">
<span class="label">34.</span><cite>Koske I, Rössler A, Pipperger L, et al.  Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment. Int J Cancer. 2019;145:1958–69. doi: 10.1002/ijc.32325.</cite> [<a href="https://doi.org/10.1002/ijc.32325" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6767478/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30972741/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int%20J%20Cancer&amp;title=Oncolytic%20virotherapy%20enhances%20the%20efficacy%20of%20a%20cancer%20vaccine%20by%20modulating%20the%20tumor%20microenvironment&amp;author=I%20Koske&amp;author=A%20R%C3%B6ssler&amp;author=L%20Pipperger&amp;volume=145&amp;publication_year=2019&amp;pages=1958-69&amp;pmid=30972741&amp;doi=10.1002/ijc.32325&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R35">
<span class="label">35.</span><cite>Mistarz A, Winkler M, Battaglia S, et al.  Reprogramming the tumor microenvironment leverages CD8+ T cell responses to a shared tumor/self antigen in ovarian cancer. Mol Ther Oncolytics. 2023;28:230–48. doi: 10.1016/j.omto.2023.02.002.</cite> [<a href="https://doi.org/10.1016/j.omto.2023.02.002" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9982455/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36875325/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Mol%20Ther%20Oncolytics&amp;title=Reprogramming%20the%20tumor%20microenvironment%20leverages%20CD8+%20T%20cell%20responses%20to%20a%20shared%20tumor/self%20antigen%20in%20ovarian%20cancer&amp;author=A%20Mistarz&amp;author=M%20Winkler&amp;author=S%20Battaglia&amp;volume=28&amp;publication_year=2023&amp;pages=230-48&amp;pmid=36875325&amp;doi=10.1016/j.omto.2023.02.002&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R36">
<span class="label">36.</span><cite>Gujar SA, Marcato P, Pan D, et al.  Reovirus virotherapy overrides tumor antigen presentation evasion and promotes protective antitumor immunity. Mol Cancer Ther. 2010;9:2924–33. doi: 10.1158/1535-7163.MCT-10-0590.</cite> [<a href="https://doi.org/10.1158/1535-7163.MCT-10-0590" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20978162/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Mol%20Cancer%20Ther&amp;title=Reovirus%20virotherapy%20overrides%20tumor%20antigen%20presentation%20evasion%20and%20promotes%20protective%20antitumor%20immunity&amp;author=SA%20Gujar&amp;author=P%20Marcato&amp;author=D%20Pan&amp;volume=9&amp;publication_year=2010&amp;pages=2924-33&amp;pmid=20978162&amp;doi=10.1158/1535-7163.MCT-10-0590&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R37">
<span class="label">37.</span><cite>Cassetti MC, McElhiney SP, Shahabi V, et al.  Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes. Vaccine (Auckl) 2004;22:520–7. doi: 10.1016/j.vaccine.2003.07.003.</cite> [<a href="https://doi.org/10.1016/j.vaccine.2003.07.003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/14670335/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Vaccine%20(Auckl)&amp;title=Antitumor%20efficacy%20of%20Venezuelan%20equine%20encephalitis%20virus%20replicon%20particles%20encoding%20mutated%20HPV16%20E6%20and%20E7%20genes&amp;author=MC%20Cassetti&amp;author=SP%20McElhiney&amp;author=V%20Shahabi&amp;volume=22&amp;publication_year=2004&amp;pages=520-7&amp;pmid=14670335&amp;doi=10.1016/j.vaccine.2003.07.003&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R38">
<span class="label">38.</span><cite>Landskron G, De la Fuente M, Thuwajit P, et al.  Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res. 2014;2014:149185.  doi: 10.1155/2014/149185.</cite> [<a href="https://doi.org/10.1155/2014/149185" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4036716/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24901008/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Immunol%20Res&amp;title=Chronic%20inflammation%20and%20cytokines%20in%20the%20tumor%20microenvironment&amp;author=G%20Landskron&amp;author=M%20De%20la%20Fuente&amp;author=P%20Thuwajit&amp;volume=2014&amp;publication_year=2014&amp;pages=149185&amp;pmid=24901008&amp;doi=10.1155/2014/149185&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R39">
<span class="label">39.</span><cite>Kim KJ, Moon D, Kong SJ, et al.  Antitumor effects of IL-12 and GM-CSF co-expressed in an engineered oncolytic HSV-1. Gene Ther. 2021;28:186–98. doi: 10.1038/s41434-020-00205-x.</cite> [<a href="https://doi.org/10.1038/s41434-020-00205-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33149278/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Gene%20Ther&amp;title=Antitumor%20effects%20of%20IL-12%20and%20GM-CSF%20co-expressed%20in%20an%20engineered%20oncolytic%20HSV-1&amp;author=KJ%20Kim&amp;author=D%20Moon&amp;author=SJ%20Kong&amp;volume=28&amp;publication_year=2021&amp;pages=186-98&amp;pmid=33149278&amp;doi=10.1038/s41434-020-00205-x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R40">
<span class="label">40.</span><cite>Choi KJ, Zhang SN, Choi IK, et al.  Strengthening of antitumor immune memory and prevention of thymic atrophy mediated by adenovirus expressing IL-12 and GM-CSF. Gene Ther. 2012;19:711–23. doi: 10.1038/gt.2011.125.</cite> [<a href="https://doi.org/10.1038/gt.2011.125" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21993173/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Gene%20Ther&amp;title=Strengthening%20of%20antitumor%20immune%20memory%20and%20prevention%20of%20thymic%20atrophy%20mediated%20by%20adenovirus%20expressing%20IL-12%20and%20GM-CSF&amp;author=KJ%20Choi&amp;author=SN%20Zhang&amp;author=IK%20Choi&amp;volume=19&amp;publication_year=2012&amp;pages=711-23&amp;pmid=21993173&amp;doi=10.1038/gt.2011.125&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R41">
<span class="label">41.</span><cite>Nguyen HM, Guz-Montgomery K, Saha D. Oncolytic Virus Encoding a Master Pro-Inflammatory Cytokine Interleukin 12 in Cancer Immunotherapy. Cells. 2020;9:400.  doi: 10.3390/cells9020400.</cite> [<a href="https://doi.org/10.3390/cells9020400" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7072539/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32050597/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cells&amp;title=Oncolytic%20Virus%20Encoding%20a%20Master%20Pro-Inflammatory%20Cytokine%20Interleukin%2012%20in%20Cancer%20Immunotherapy&amp;author=HM%20Nguyen&amp;author=K%20Guz-Montgomery&amp;author=D%20Saha&amp;volume=9&amp;publication_year=2020&amp;pages=400&amp;pmid=32050597&amp;doi=10.3390/cells9020400&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R42">
<span class="label">42.</span><cite>Dong C, Tan D, Sun H, et al.  Interleukin-12 Delivery Strategies and Advances in Tumor Immunotherapy. 
CIMB
. 2024;46:11548–79. doi: 10.3390/cimb46100686.</cite> [<a href="https://doi.org/10.3390/cimb46100686" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11506767/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39451566/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=CIMB&amp;title=Interleukin-12%20Delivery%20Strategies%20and%20Advances%20in%20Tumor%20Immunotherapy&amp;author=C%20Dong&amp;author=D%20Tan&amp;author=H%20Sun&amp;volume=46&amp;publication_year=2024&amp;pages=11548-79&amp;pmid=39451566&amp;doi=10.3390/cimb46100686&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R43">
<span class="label">43.</span><cite>Ryapolova A, Minskaia E, Gasanov N, et al.  Development of Recombinant Oncolytic rVSV-mIL12-mGMCSF for Cancer Immunotherapy. Int J Mol Sci. 2023;25:211.  doi: 10.3390/ijms25010211.</cite> [<a href="https://doi.org/10.3390/ijms25010211" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10779112/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38203382/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int%20J%20Mol%20Sci&amp;title=Development%20of%20Recombinant%20Oncolytic%20rVSV-mIL12-mGMCSF%20for%20Cancer%20Immunotherapy&amp;author=A%20Ryapolova&amp;author=E%20Minskaia&amp;author=N%20Gasanov&amp;volume=25&amp;publication_year=2023&amp;pages=211&amp;pmid=38203382&amp;doi=10.3390/ijms25010211&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R44">
<span class="label">44.</span><cite>Shin EJ, Wanna GB, Choi B, et al.  Interleukin‐12 Expression Enhances Vesicular Stomatitis Virus Oncolytic Therapy in Murine Squamous Cell Carcinoma. Laryngoscope. 2007;117:210–4. doi: 10.1097/01.mlg.0000246194.66295.d8.</cite> [<a href="https://doi.org/10.1097/01.mlg.0000246194.66295.d8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17204993/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Laryngoscope&amp;title=Interleukin%E2%80%9012%20Expression%20Enhances%20Vesicular%20Stomatitis%20Virus%20Oncolytic%20Therapy%20in%20Murine%20Squamous%20Cell%20Carcinoma&amp;author=EJ%20Shin&amp;author=GB%20Wanna&amp;author=B%20Choi&amp;volume=117&amp;publication_year=2007&amp;pages=210-4&amp;pmid=17204993&amp;doi=10.1097/01.mlg.0000246194.66295.d8&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R45">
<span class="label">45.</span><cite>Vitale I, Shema E, Loi S, et al.  Intratumoral heterogeneity in cancer progression and response to immunotherapy. Nat Med. 2021;27:212–24. doi: 10.1038/s41591-021-01233-9.</cite> [<a href="https://doi.org/10.1038/s41591-021-01233-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33574607/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Med&amp;title=Intratumoral%20heterogeneity%20in%20cancer%20progression%20and%20response%20to%20immunotherapy&amp;author=I%20Vitale&amp;author=E%20Shema&amp;author=S%20Loi&amp;volume=27&amp;publication_year=2021&amp;pages=212-24&amp;pmid=33574607&amp;doi=10.1038/s41591-021-01233-9&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R46">
<span class="label">46.</span><cite>Shah S, Grotenbreg GM, Rivera A, et al.  An extrafollicular pathway for the generation of effector CD8(+) T cells driven by the proinflammatory cytokine, IL-12. Elife. 2015;4:e09017.  doi: 10.7554/eLife.09017.</cite> [<a href="https://doi.org/10.7554/eLife.09017" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4549662/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26244629/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Elife&amp;title=An%20extrafollicular%20pathway%20for%20the%20generation%20of%20effector%20CD8(+)%20T%20cells%20driven%20by%20the%20proinflammatory%20cytokine,%20IL-12&amp;author=S%20Shah&amp;author=GM%20Grotenbreg&amp;author=A%20Rivera&amp;volume=4&amp;publication_year=2015&amp;pages=e09017&amp;pmid=26244629&amp;doi=10.7554/eLife.09017&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R47">
<span class="label">47.</span><cite>Telli ML, Nagata H, Wapnir I, et al.  Intratumoral Plasmid IL12 Expands CD8+ T Cells and Induces a CXCR3 Gene Signature in Triple-negative Breast Tumors that Sensitizes Patients to Anti-PD-1 Therapy. 
Clin Cancer Res
. 2021;27:2481–93. doi: 10.1158/1078-0432.CCR-20-3944.</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-20-3944" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8102331/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33593880/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Cancer%20Res&amp;title=Intratumoral%20Plasmid%20IL12%20Expands%20CD8+%20T%20Cells%20and%20Induces%20a%20CXCR3%20Gene%20Signature%20in%20Triple-negative%20Breast%20Tumors%20that%20Sensitizes%20Patients%20to%20Anti-PD-1%20Therapy&amp;author=ML%20Telli&amp;author=H%20Nagata&amp;author=I%20Wapnir&amp;volume=27&amp;publication_year=2021&amp;pages=2481-93&amp;pmid=33593880&amp;doi=10.1158/1078-0432.CCR-20-3944&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R48">
<span class="label">48.</span><cite>van Herpen CM, Looman M, Zonneveld M, et al.  Intratumoral administration of recombinant human interleukin 12 in head and neck squamous cell carcinoma patients elicits a T-helper 1 profile in the locoregional lymph nodes. Clin Cancer Res. 2004;10:2626–35. doi: 10.1158/1078-0432.ccr-03-0304.</cite> [<a href="https://doi.org/10.1158/1078-0432.ccr-03-0304" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15102664/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Cancer%20Res&amp;title=Intratumoral%20administration%20of%20recombinant%20human%20interleukin%2012%20in%20head%20and%20neck%20squamous%20cell%20carcinoma%20patients%20elicits%20a%20T-helper%201%20profile%20in%20the%20locoregional%20lymph%20nodes&amp;author=CM%20van%20Herpen&amp;author=M%20Looman&amp;author=M%20Zonneveld&amp;volume=10&amp;publication_year=2004&amp;pages=2626-35&amp;pmid=15102664&amp;doi=10.1158/1078-0432.ccr-03-0304&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R49">
<span class="label">49.</span><cite>Zhang L, Morgan RA, Beane JD, et al.  Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma. Clin Cancer Res. 2015;21:2278–88. doi: 10.1158/1078-0432.CCR-14-2085.</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-14-2085" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4433819/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25695689/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Cancer%20Res&amp;title=Tumor-Infiltrating%20Lymphocytes%20Genetically%20Engineered%20with%20an%20Inducible%20Gene%20Encoding%20Interleukin-12%20for%20the%20Immunotherapy%20of%20Metastatic%20Melanoma&amp;author=L%20Zhang&amp;author=RA%20Morgan&amp;author=JD%20Beane&amp;volume=21&amp;publication_year=2015&amp;pages=2278-88&amp;pmid=25695689&amp;doi=10.1158/1078-0432.CCR-14-2085&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R50">
<span class="label">50.</span><cite>Chakrabarti R, Chang Y, Song K, et al.  Plasmids encoding membrane-bound IL-4 or IL-12 strongly costimulate DNA vaccination against carcinoembryonic antigen (CEA) Vaccine (Auckl) 2004;22:1199–205. doi: 10.1016/j.vaccine.2003.09.023.</cite> [<a href="https://doi.org/10.1016/j.vaccine.2003.09.023" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15003648/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Vaccine%20(Auckl)&amp;title=Plasmids%20encoding%20membrane-bound%20IL-4%20or%20IL-12%20strongly%20costimulate%20DNA%20vaccination%20against%20carcinoembryonic%20antigen%20(CEA)&amp;author=R%20Chakrabarti&amp;author=Y%20Chang&amp;author=K%20Song&amp;volume=22&amp;publication_year=2004&amp;pages=1199-205&amp;pmid=15003648&amp;doi=10.1016/j.vaccine.2003.09.023&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R51">
<span class="label">51.</span><cite>Böttcher JP, Beyer M, Meissner F, et al.  Functional classification of memory CD8(+) T cells by CX3CR1 expression. Nat Commun. 2015;6:8306.  doi: 10.1038/ncomms9306.</cite> [<a href="https://doi.org/10.1038/ncomms9306" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4667439/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26404698/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Commun&amp;title=Functional%20classification%20of%20memory%20CD8(+)%20T%20cells%20by%20CX3CR1%20expression&amp;author=JP%20B%C3%B6ttcher&amp;author=M%20Beyer&amp;author=F%20Meissner&amp;volume=6&amp;publication_year=2015&amp;pages=8306&amp;pmid=26404698&amp;doi=10.1038/ncomms9306&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R52">
<span class="label">52.</span><cite>Martin MD, Badovinac VP. Defining Memory CD8 T Cell. Front Immunol. 2018;9:2692.  doi: 10.3389/fimmu.2018.02692.</cite> [<a href="https://doi.org/10.3389/fimmu.2018.02692" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6255921/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30515169/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front%20Immunol&amp;title=Defining%20Memory%20CD8%20T%20Cell&amp;author=MD%20Martin&amp;author=VP%20Badovinac&amp;volume=9&amp;publication_year=2018&amp;pages=2692&amp;pmid=30515169&amp;doi=10.3389/fimmu.2018.02692&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R53">
<span class="label">53.</span><cite>Plumlee CR, Obar JJ, Colpitts SL, et al.  Early Effector CD8 T Cells Display Plasticity in Populating the Short-Lived Effector and Memory-Precursor Pools Following Bacterial or Viral Infection. Sci Rep. 2015;5:12264.  doi: 10.1038/srep12264.</cite> [<a href="https://doi.org/10.1038/srep12264" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4507483/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26191658/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Sci%20Rep&amp;title=Early%20Effector%20CD8%20T%20Cells%20Display%20Plasticity%20in%20Populating%20the%20Short-Lived%20Effector%20and%20Memory-Precursor%20Pools%20Following%20Bacterial%20or%20Viral%20Infection&amp;author=CR%20Plumlee&amp;author=JJ%20Obar&amp;author=SL%20Colpitts&amp;volume=5&amp;publication_year=2015&amp;pages=12264&amp;pmid=26191658&amp;doi=10.1038/srep12264&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R54">
<span class="label">54.</span><cite>Joshi NS, Cui W, Chandele A, et al.  Inflammation directs memory precursor and short-lived effector CD8(+) T cell fates via the graded expression of T-bet transcription factor. Immunity. 2007;27:281–95. doi: 10.1016/j.immuni.2007.07.010.</cite> [<a href="https://doi.org/10.1016/j.immuni.2007.07.010" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2034442/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17723218/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Immunity&amp;title=Inflammation%20directs%20memory%20precursor%20and%20short-lived%20effector%20CD8(+)%20T%20cell%20fates%20via%20the%20graded%20expression%20of%20T-bet%20transcription%20factor&amp;author=NS%20Joshi&amp;author=W%20Cui&amp;author=A%20Chandele&amp;volume=27&amp;publication_year=2007&amp;pages=281-95&amp;pmid=17723218&amp;doi=10.1016/j.immuni.2007.07.010&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adsm93_" lang="en" class="supplementary-materials"><h3 class="pmc_sec_title">Supplementary Materials</h3>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="caption p"><span>online supplemental file 1</span></div>
<div class="media p">
<div class="caption">
<a href="/articles/instance/12366581/bin/jitc-13-8-s001.docx" data-ga-action="click_feat_suppl" class="usa-link">jitc-13-8-s001.docx</a><sup> (35.3MB, docx) </sup>
</div>
<div class="object-id font-xs text-base-dark">DOI: 10.1136/jitc-2024-010675</div>
</div></section></section><section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>All data relevant to the study are included in the article or uploaded as supplementary information.</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Journal for Immunotherapy of Cancer are provided here courtesy of <strong>BMJ Publishing Group</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1136/jitc-2024-010675"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/jitc-13-8.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (5.5 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12366581/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12366581/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12366581%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12366581/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12366581/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12366581/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40835316/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12366581/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40835316/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12366581/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12366581/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="F1DxYXaAdfGy2Qj1by2NyzHbc1ArXdgBMFSmre815DXthVQvxDjw3BE8vspgDYHu">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
